Exhibit 1

191232324949445hl Doboo 3950-Eile of De do 033206/210 nt exercise 024033220612602690274:2131 air Extribit much Copy of KPMG First Monthly of 64Application Pg 2 of 85

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

In re: Chapter 11

PURDUE PHARMA L.P., et al., : Case No. 19-23649 (RDD)

Debtors.¹ : (Jointly Administered)

:

FIRST MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES INCURRED AS TAX CONSULTANT FOR THE DEBTORS AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FOR THE PERIOD FROM DECEMBER 23, 2019 THROUGH JANUARY 31, 2020

Name of Applicant: KPMG LLP

Authorized to Provide Professional Services to:

The Debtors and the Official Committee of

Unsecured Creditors

Date of Retention: February 24, 2020, nunc pro tunc to

December 23, 2019

Period for Which Compensation and December 23, 2019 through

Reimbursement is Sought: January 31, 2020

Amount of Compensation Sought as Actual,

Reasonable, and Necessary: \$ 580,539.30

Less 20% Holdback: \$ (116,107.86)

Amount of Expense Reimbursement Sought as

Actual, Reasonable, and Necessary: \$ 614.93

Total Fees and Expenses Due: \$ 465,046.37

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

1912328264944shl Doboo & 9350-Eile of iDedo 033206/210 nt exercte 02d0 03320612602690274:2131 air Extribit ribent Copy of KPMG First Monthly of 644Application Pg 3 of 85

Dated: March 2, 2020

/s/ Howard Steinberg
Howard Steinberg
KPMG LLP
1350 Avenue of the Americas
New York, New York 10019
(212) 872-6562

19123236494shl Dobo&9350-EileoFiDedO332106/210nteEnteroedO3321061260269024:2131ainEtatibitrollent Copy of KPMG First Monthly offeedApplication Pg 4 of 85

EXHIBIT A

Purdue Pharma L.P. Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional December 23, 2019 through January 31, 2020

Andy Farinich	Professional Person	Position & Department	Country of Origin	Total Billed Hours	Hou Billing	•	Co	Total ompensation
Anja Poel	Andre English	Soniar Associate International Tax	HC	65.1	¢	524	¢	24 022 60
Arike Tytan	•							
Arcent Rambhadjan	•	_						
Arpit Desai	•							
Arpit Kakar Senior Associate - Tax India 2.8 5.40 5.1,792.00	•							
Ashley Armfield Senior Associate - M&A Tax Italy 0.6 \$ 640 \$ 343.00	-	_						
Carlotta Bertu Senior Associate - Tax Italy 0.6 \$ 640 \$ 334,00 Casey Nunez Senior Manager - M&A Tax US 32.7 744 \$ 24,328.80 Christian Schmid Partner - Int'l Tax Germany 5.5 \$ 985 \$ 5,417.50 Christin Witt Manager - German Int'l Tax US 0.4 \$ 650 \$ 20,000 Danielle Moloughney Associate - Tax US 15.07 \$ 695 \$ 104,736.50 Dawn Krishnamurthy Manager - M&A Tax US 125.0 \$ 350 \$ 43,750.00 Devon Rowles Associate - M&A Tax US 125.0 \$ 350 \$ 43,750.00 Douglas Holland Principal - Washington National Tax US 1.1 \$ 985 \$ 1,083.50 Frank Caratzola Senior Associate - Int'l Tax US 20.7 \$ 534 \$ 11,053.80 Gray Bell Partner - Tax UK 2.23 \$ 985 \$ 2,265.50 Gregory Bell Partner - Tax US 27.4 \$ 856 \$ 22,455.00 Gr	*							
Casey Nunez	•							
Christian Schmid			•					
Christin Witt	-							
Danielle Moloughney Associate - Tax			•					
Dawn Krishnamurthy Manager - M&A Tax		•						
Devon Rowles								
Dong-Ju Shin	•							
Douglas Holland								
Frank Caratzola Senior Associate - Intl' Tax US 20.7 \$ 534 \$ 11,053.80	_	_						
Gavin Little Managing Director - Tax UK 2.3 \$ 985 \$ 2,265.50 Gregory Bell Partner - Tax Canada 1.5 \$ 743 \$ 1,114.50 Howard Steinberg Partner - M&A Tax US 27.4 \$ 856 \$ 23,454.40 Isaac Hirsch Managing Director - Int'l Tax US 79.1 \$ 819 \$ 64,782.90 Jess Commisso Associate - M&A Tax US 170.1 \$ 350 \$ 59,535.00 Jonas Lau Senior Manager - Tax US 170.1 \$ 350 \$ 59,535.00 Karl Tong Manager - Tax US 5.6 \$ 690 \$ 3,864.00 Kees Van Meel Principal - Int'l Tax US 0.5 \$ 757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 730 \$ 5,256.00 Maggie Scully Ass	_	· -						*
Gregory Bell Partner - Tax Canada 1.5 \$ 743 \$ 1,114.50 Howard Steinberg Partner - M&A Tax US 27.4 \$ 856 \$ 23,454.40 Isaac Hirsch Managing Director - Int'l Tax US 79.1 \$ 819 \$ 64,782.90 Jess Commisso Associate - M&A Tax US 170.1 \$ 350 \$ 59,535.00 Jonas Lau Senior Manager - Tax Canada 5.5 614 \$ 3,377.00 Karen Erickson Senior Manager - Tax US 5.6 690 \$ 3,864.00 Karl Tong Manager - Tax US 5.5 690 \$ 3,864.00 Kees Van Meel Principal - Int'l Tax US 5.5 5757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Maggie Scully Associat								
Howard Steinberg Partner - M&A Tax US 27.4 \$ 856 \$ 23,454.40 Isaac Hirsch Managing Director - Int'l Tax US 79.1 \$ 819 \$ 64,782.90 Jess Commisso Associate - M&A Tax US 170.1 \$ 350 \$ 59,535.00 Jonas Lau Senior Manager - Tax Canada 5.5 \$ 614 \$ 3,377.00 Karen Erickson Senior Manager - Tax US 5.6 \$ 690 \$ 3,864.00 Karl Tong Manager - Tax US 5.6 \$ 690 \$ 3,864.00 Karl Tong Manager - Tax US 0.5 \$ 757 \$ 378.50 Kees Van Meel Principal - Int'l Tax US 0.5 \$ 757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Nick Morgan Associate - M&A Tax US 11.1 \$ 534 \$ 59,647.80 Nick Morgan Associate - Max Tax US 11.2 \$ 350 \$ 4,515.00 Nichal Jain Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,240.00 Oron Zeevi Senior Manager - Tax US 14 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Washington National Tax US 14 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - German Intl Tax US 3.2 \$ 350 \$ 1,120.00 Philipp Reer Partner - German Intl Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60 Sam Tyler Partner - Tax Canada								
Isaac Hirsch Managing Director - Int'l Tax US 79.1 \$ 819 \$ 64,782.90 Jess Commisso Associate - M&A Tax US 170.1 \$ 350 \$ 59,535.00 Jonas Lau Senior Manager - Tax Canada 5.5 \$ 614 \$ 3,377.00 Karen Erickson Senior Manager - Tax US 5.6 \$ 690 \$ 3,864.00 Karl Tong Manager - Tax US 5.6 \$ 690 \$ 3,864.00 Karl Tong Manager - Tax US 0.5 \$ 757 \$ 378.50 Kees Van Meel Principal - Int'l Tax US 0.5 \$ 757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 3.1 \$ 534 \$ 59,647.80 Monica Plangman Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 3.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 3.2 \$ 350 \$ 6,710.00 Philipp Reer Partner - German Intl Tax US 3.2 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - German Intl Tax US 3.2 \$ 743 \$ 2,377.60 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60 Jess Commissoo Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60 Jess Commissoo Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60 J								
Jess Commisso	C							
Senior Manager - Tax								
Karen Erickson Senior Manager - Tax US 5.6 \$ 690 \$ 3,864.00 Karl Tong Manager - Tax China 0.3 \$ 594 \$ 178.20 Kees Van Meel Principal - Int'l Tax US 0.5 \$ 757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 3.6 \$ 264 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Nich Morga								
Karl Tong Manager - Tax China 0.3 \$ 594 \$ 178.20 Kees Van Meel Principal - Int'l Tax US 0.5 \$ 757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptey US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick M		_						
Kees Van Meel Principal - Int'l Tax US 0.5 \$ 757 \$ 378.50 Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 <t< td=""><td></td><td>_</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		_						
Kyung-Min Kim Senior Manager - Tax South Korea 1.0 \$ 750 \$ 750.00 Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00		_						
Lorenzo Bellavite Partner - Tax Italy 0.5 \$ 985 \$ 492.50 Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 640 \$ 2,240.00 Oron Zeevi Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60		*						
Lukas van der Veen Manager - Tax Netherlands 7.2 \$ 730 \$ 5,256.00 Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60		_						
Madeleine Latham Associate - Tax UK 4.4 \$ 380 \$ 1,672.00 Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00			•					
Maggie Scully Associate - M&A Tax US 3.1 \$ 350 \$ 1,085.00 Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 3.2 \$ 350 \$ 1,120.00		2						*
Mark Hoffenberg Principal - Washington National Tax US 6.3 \$ 980 \$ 6,174.00 Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60								
Michael Land Senior Associate - M&A Tax US 111.7 \$ 534 \$ 59,647.80 Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60								
Monica Plangman Associate Director - Bankruptcy US 3.6 \$ 264 \$ 950.40 Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60	•	· -						
Naman Gupta Senior Associate - Tax India 3.1 \$ 640 \$ 1,984.00 Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 743 \$ 2,377.60								*
Nick Morgan Associate - M&A Tax US 12.9 \$ 350 \$ 4,515.00 Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 743 \$ 2,377.60	_	- · ·						
Nidhi Jain Senior Associate - Tax India 3.5 \$ 640 \$ 2,240.00 Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60	-							
Oron Zeevi Senior Manager - Tax Israel 5.5 \$ 450 \$ 2,475.00 Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60								
Paul Kunkel Senior Manager - Washington National Tax US 1.4 \$ 744 \$ 1,041.60 Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60								
Pete DiMatteo Manager - Int'l Tax US 93.4 \$ 650 \$ 60,710.00 Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60		_						
Philipp Reer Partner - German Intl Tax US 4.5 \$ 765 \$ 3,442.50 Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60		2						
Renay Gosen Associate - M&A Tax US 3.2 \$ 350 \$ 1,120.00 Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60			US				\$	
Sam Tyler Partner - Tax Canada 3.2 \$ 743 \$ 2,377.60	* *							
	•				\$		\$	
Sonia Stricker Associate - Tax Germany 28.3 \$ 380 \$ 10.754.00	•						\$	
Some Salester 1 1050 σ 10,754.00	Sonia Stricker	Associate - Tax	Germany	28.3	\$	380	\$	10,754.00

KPMG LLP Monthly Fee Statement Page 1 of 82

1912/312/3104/94/shl Doboo & 9250-Eile of iDed/0033206/210 nterente of ed/0033206/12/026902/4:218/1ain Editibit muent Copy of KPMG First Morthly of the Application Pg 5 of 85

EXHIBIT A

Purdue Pharma L.P. Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional December 23, 2019 through January 31, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours		ourly ng Rate	C	Total ompensation
Thomas Giordano	Associate - Int'l Tax	US	148.3	\$	350	\$	51,905.00
Thomas Heubach	Senior Manager - Tax	Germany	23.5	\$	750	\$	17,625.00
Tracy Stone	Principal - Washington National Tax	US	1.3	\$	906	\$	1,177.80
Wendy Shaffer	Manager - Bankruptcy	US	33.7	\$	202	\$	6,807.40
Less 50% Rate Reduction related to Non-Working Travel Time						\$	(2,457.00)
Subtotal of Hours and Discounted Fees 1,354.5						\$	712,996.30
Less KPMG Voluntary Re	duction (See Exhibit C1)					\$	(130,000.00)
Less KPMG Voluntary Re	duction (See Exhibit C2)					\$	$(2,457.00)^{(1)}$
Total Discounted Fees						\$	580,539.30
Total Out of Pocket Exper	ases					\$	989.04
Voluntary Reduction in Ex	penses					\$	(374.11)
Total Out of Pocket Expo	enses After Voluntary Reduction					\$	614.93 (2)
Total Fees and Out of Po	cket Expenses					\$	581,154.23
Less Holdback Adjustmen	-					\$	(116,107.86)
Net Requested Fees & O						\$	465,046.37
Blended Hourly Rate				\$	428.60		

⁽¹⁾ KPMG is taking a voluntary reduction of non-working travel time.

KPMG LLP Monthly Fee Statement Page 2 of 82

⁽²⁾ See Exhibit D and D1 for an explanation of the expenses and the voluntary reduction.

1912328240494shl Doboo & 9350-Eile of iDedo 233206/210 nt exercte of 200332061250269024:2131 air Editibit rilent Copy of KPMG First Morthly off each Application Pg 6 of 85

EXHIBIT B

Purdue Pharma L.P. Case No. 19-23649

Summary of Hours and Discounted Fees Incurred by Category December 23, 2019 through January 31, 2020

Category	Exhibit	Total Billed Hours	Total Fees Requested
Bankruptcy Tax Consulting Services	C1	1,311.1	\$ 572,712.00
Non -Working Travel Time	C2	6.0	\$ -
Retention Services	C3	3.6	\$ 950.40
Fee Application Prepration Services	C4	33.8	\$ 6,876.90
Total		1,354.5	\$ 580,539.30

KPMG LLP Monthly Fee Statement Page 3 of 82

1912323249494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First Monthly offee4Application Pg 7 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	ate	Amount
Isaac Hirsch	12/26/19	Call with I. Hirsch - partial attendance, M. Hoffenberg and H. Steinberg (all KPMG) to discuss Pharma project work plan and services to be provided by KPMG member firms.	0.5	\$	819	\$ 409.50
Howard Steinberg	12/26/19	Call with I. Hirsch - partial attendance, M. Hoffenberg and H. Steinberg (all KPMG) to discuss Pharma project work plan and services to be provided by KPMG member firms.	0.8	\$	856	\$ 684.80
Mark Hoffenberg	12/26/19	Call with I. Hirsch - partial attendance, M. Hoffenberg and H. Steinberg (all KPMG) to discuss Pharma project work plan and services to be provided by KPMG member firms.	0.8	\$	980	\$ 784.00
Isaac Hirsch	12/29/19	Performed International Tax Managing Director review and concurrently comment on initial draft of KPMG Purdue workplan	1.0	\$	819	\$ 819.00
Devon Rowles	12/30/19	Updates to the information request list (IRL) with more detail regarding required data to complete a request pursuant to receiving all documents for deliverables	1.1	\$	350	\$ 385.00
Devon Rowles	12/30/19	Began tracking designated portion of revenue, for numerous Mundipharma entities, in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.	1.7	\$	350	\$ 595.00
Michael Land	12/30/19	(1.8) Preparation of initial workplan related to Purdue Pharma tax consulting; (0.4) review of virtual data room information (provided by client) as of 12/30/19 related to potential tax information of the independent associated companies	2.2	\$	534	\$ 1,174.80
Devon Rowles	12/30/19	Drafting the US information request list pursuant to reviewing and concurrently organizing documents necessary to complete deliverables.	2.3	\$	350	\$ 805.00
Devon Rowles	12/30/19	Recording revenues for the various jurisdictions, for KPMG member firms we have already engaged, in order to prioritize those jurisdictions for the engagement.	2.9	\$	350	\$ 1,015.00
Michael Land	12/30/19	Review of initial summary of gross revenue on an entity-by- entity basis to determine high priority jurisdictions	2.9	\$	534	\$ 1,548.60
Jess Commisso	12/30/19	Review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00
Casey Nunez	12/31/19	Performed senior manager review of master workplan draft as requested by client.	0.6	\$	744	\$ 446.40
Jess Commisso	12/31/19	Continue, from earlier in the day, to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	0.7	\$	350	\$ 245.00

KPMG LLP Monthly Fee Statement Page 4 of 82

1912323249494shl Doboo 89350-Eile of 1020/0332106/210 nt exercte 020/033210612502690274:2181 air Extribit ribent Copy of KPMG First Monthly of each Application Pg 8 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Jess Commisso	12/31/19	Updating virtual data room (VDR) tracker / revenue breakdown with regards to additional documentation received as of 12/31 to update our Mundipharma jurisdiction revenue breakdown - pursuant to determining priority jurisdictions for assistance by KPMG member firms.	1.9	\$	350	\$ 665.00
Devon Rowles	12/31/19	Continued (from 12/30) to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.	3.3	\$	350	\$ 1,155.00
Jess Commisso	12/31/19	Continued (from 12/30) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00
Dawn Krishnamurthy	01/02/20	0.1 Manager review of draft email to KPMG member firms requesting their high priority tax information requests; 0.3 Review of Purdue Term Sheet filed on docket for purpose of gaining insight regarding potential tax issues related to proposed transactions.	0.4	\$	695	\$ 278.00
Ashley Armfield	01/02/20	Review of latest version of Purdue Information Request List and concurrently providing comments to M. Land (KPMG).	0.6	\$	534	\$ 320.40
Pete DiMatteo	01/02/20		0.7	\$	650	\$ 455.00
Casey Nunez	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$	744	\$ 595.20
Dawn Krishnamurthy	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$	695	\$ 556.00
Howard Steinberg	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$	856	\$ 684.80
Isaac Hirsch	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$	819	\$ 655.20

KPMG LLP Monthly Fee Statement Page 5 of 82

1912323249494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First Monthly offee4Application Pg 9 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours]	Rate	Amount
Michael Land	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$	534	\$ 427.20
Pete DiMatteo	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$	650	\$ 520.00
Isaac Hirsch	01/02/20	Meeting with P. DiMatteo and I. Hirsch (both KPMG) to review and concurrently discuss information request listing for purposes of determining strategy for preparing preliminary modeling	1.0	\$	819	\$ 819.00
Pete DiMatteo	01/02/20	Meeting with P. DiMatteo and I. Hirsch (both KPMG) to review and concurrently discuss information request listing for purposes of determining strategy for preparing preliminary modeling	1.0	\$	650	\$ 650.00
Casey Nunez	01/02/20	(0.8) Senior manager revisions to updated version of workplan as requested by clients; (0.7) performed senior manager review of updated information request list; (0.4) communication via email to KPMG foreign member firms regarding work plan / information request list.	1.9	\$	744	\$ 1,413.60
Michael Land	01/02/20	(1.1) Review and concurrently update workplan related to US documents needed to gain insight regarding the independent associated companies' tax profile; (0.8) review of virtual data room documents, as of 1/2/2020, related to potential tax information of the independent associated companies	1.9	\$	534	\$ 1,014.60
Isaac Hirsch	01/02/20	Review Norton Rose analysis of high level tax consequences of straw man settlement and concurrently brainstorm with regards to the structure of the KPMG cash tax cost model	2.2	\$	819	\$ 1,801.80
Michael Land	01/02/20	(1.2) Preparation of initial information request list related to US documents needed to gain insight regarding the independent associated companies' tax profile; (1.2) Updated initial information request list with regards to manager comments received as of 1/2/2020.	2.4	\$	534	\$ 1,281.60
Michael Land	01/02/20	Review and concurrently update independent associated company summary file to determine priority of jurisdictions	3.1	\$	534	\$ 1,655.40

KPMG LLP Monthly Fee Statement Page 6 of 82

1912323049494shl D@0089350-EiledFi02d0332106/210nteEntel02d03321061250269024:2181ainEtatibitment Copy of KPMG First MonRtyly 15684Application Pg 10 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Isaac Hirsch	01/02/20	(1.2) Performed International Tax Managing Director review and concurrently comment on updated draft KPMG workplan / information request list provided by C. Nunez; (0.6) email communication with C. Nunez (KPMG) regarding comments related to draft KPMG workplan / information request list; (1.9) review documentation in virtual data room (provided by client) for purposes of analyzing potential cash tax cost of straw man settlement agreement	3.7	\$	819	\$ 3,030.30
Karl Tong	01/03/20		0.3	\$	594	\$ 178.20
Pete DiMatteo	01/03/20	Prepare template to be utilized for purposes of creating organization charts depicting relevant entities to assist with transaction structuring.	0.5	\$	650	\$ 325.00
Jess Commisso	01/03/20	Prepared for upcoming call with project team (on same day) by consolidating project team notes (from previous meetings) to identify items requiring follow-up / tasks to be discussed in upcoming meeting.	0.5	\$	350	\$ 175.00
Ashley Armfield	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$	534	\$ 320.40
Casey Nunez	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$	744	\$ 446.40
Dawn Krishnamurthy	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$	695	\$ 417.00
Howard Steinberg	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$	856	\$ 513.60
Isaac Hirsch	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$	819	\$ 491.40
Mark Hoffenberg	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$	980	\$ 588.00

KPMG LLP Monthly Fee Statement Page 7 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Michael Land	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$ 534	\$ 320.40
Pete DiMatteo	01/03/20	Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.	0.6	\$ 650	\$ 390.00
Paul Kunkel	01/03/20	Reviewed document "9/15/19 "Notice of Filing of Term Sheet With Ad Hoc Committee "in order to get a sense of the transactions that have been proposed to settle the bankruptcy case.	0.6	\$ 744	\$ 446.40
Casey Nunez	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$ 744	\$ 595.20
Devon Rowles	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$ 350	\$ 280.00
Howard Steinberg	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$ 856	\$ 684.80
Isaac Hirsch	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$ 819	\$ 655.20
Jess Commisso	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$ 350	\$ 280.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/Ily1Fee8Application Pg 12 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	Rate	Amount
Mark Hoffenberg	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$	980	\$ 784.00
Michael Land	01/03/20		0.8	\$	534	\$ 427.20
Paul Kunkel	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$	744	\$ 595.20
Pete DiMatteo	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling.	0.8	\$	650	\$ 520.00
Michael Land	01/03/20	Revised initial information requests lists to incorporate Member Firm input	0.8	\$	534	\$ 427.20
Philipp Reer	01/03/20	Performed Partner review of German proposed tax workplan (provided by C. Nunez) and concurrently modified as needed.	1.0	\$	765	\$ 765.00
Isaac Hirsch	01/03/20	Conference with I. Hirsch and P. DiMatteo (Both KPMG) to discuss issues related to organization charts, potential deductions arising from settlement payments, and direction with respect to research to be performed regarding same	1.1	\$	819	\$ 900.90
Pete DiMatteo	01/03/20	Conference with I. Hirsch and P. DiMatteo (Both KPMG) to discuss issues related to organization charts, potential deductions arising from settlement payments, and direction with respect to research to be performed regarding same	1.1	\$	650	\$ 715.00
Casey Nunez	01/03/20	Performed senior manager review of updates to US tax workplan as requested by client	1.2	\$	744	\$ 892.80
Anja Poesl	01/03/20	Review draft Workplan along with draft Information Request List for Germany as provided by C. Nunez (KPMG) via e-mail dated January 1, 2020.	1.2	\$	750	\$ 900.00

KPMG LLP Monthly Fee Statement Page 9 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Dawn Krishnamurthy	01/03/20	0.9 Review of court filings submitted by Purdue with regards to proposed transaction and potential tax matters to be addressed; 0.2 communication via email with C. Nunez (KPMG) discussing information request/workplan additions; 0.2 Drafted email to I. Hirsch, C. Nunez, M. Land (all KPMG) to provide details related to and copy of updated Workplan.	1.3	\$	695	\$ 903.50
Tracy Stone	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling; prepare list of questions related to trust classification (0.8); drafted email to I. Hirsch and C. Nunez re same (0.5).	1.3	\$	906	\$ 1,177.80
Isaac Hirsch	01/03/20	(0.8) Performed International Tax Managing Director review and concurrently comment on latest version of KPMG workplan draft provided by KPMG M&A team; (0.8) communication via email with T. Stone and P. Kunkel (both KPMG) regarding preparation of list of questions to add to KPMG's information request concerning analysis of the trusts in the Purdue ownership structure	1.6	\$	819	\$ 1,310.40
Anja Poesl	01/03/20	0.9 Review of Purdue Term Sheet as provided to us by C. Nunez (KPMG) via e-mail dated January 1, 2020 to gain insight regarding planned steps; 0.9 Update Workplan and Information Request List - Germany in excel file, i.e. addition of documents required to prepare German Tax Profile and to perform Transaction Tax Analysis for Germany.	1.8	\$	750	\$ 1,350.00
Devon Rowles	01/03/20	(1.6) Updates to the workplans sent from KPMG foreign member firms and concurrently revise as needed; (0.3) Discussion with J. Commisso (KPMG) regarding next steps to complete the revenue by country files - as of 1/3/2020.	1.9	\$	350	\$ 665.00
Michael Land	01/03/20	Reviewed member firm initial information request lists (Israel, Italy, Germany, Netherlands, and China) in conjunction with proposed work plan	2.4	\$	534	\$ 1,281.60
Isaac Hirsch	01/03/20	(1.3) Continue (from 1/2) to review Norton Rose analysis of high level tax consequences of straw man settlement and concurrently brainstormed with regards to the KPMG cash tax cost model; (0.8) review and concurrently comment on most recent draft of KPMG workplan provided by KPMG M&A team; (0.8) communication via email with T. Stone and P. Kunkel (both KPMG) regarding preparation of list of questions to add to KPMG's information request concerning analysis of the trusts in the Purdue ownership structure.	2.9	\$	819	\$ 2,375.10

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/13/3Fee8Application Pg 14 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	late	Amount
Pete DiMatteo	01/03/20	Performed analysis regarding potential deductibility of settlement payments at the individual and trust level for purposes of assessing tax cost of contemplated transactions.	3.4	\$	650	\$ 2,210.00
Jess Commisso	01/03/20	Concurrently incorporating member firm workplans / information request lists into a Master file with KPMG United States' portion (3.1); creation of a supplemental tracker to track updates related to such items (0.5); Discussion with D. Rowles (KPMG) regarding next steps to complete the revenue by country files as of 1/3/2020 (0.3).	3.9	\$	350	\$ 1,365.00
Jess Commisso	01/03/20	Continued, from 12/31, to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00
Sam Tyler	01/05/20	Brief review of bankruptcy documentation including structure chart / information provided to-date to determine information request need for work to be performed	0.5	\$	743	\$ 371.50
Michael Land	01/05/20	Preparation of updates to preliminary workplan as well as information request list to incorporate KPMG Canada input (1.1) Communication with KPMG Canada Partner (S. Tyler) via email regarding preliminary workplan / initial request list for project strategy (0.3)	1.4	\$	534	\$ 747.60
Madeleine Latham	01/06/20	(0.1) Meeting with A. Desai and M. Latham (both KPMG UK) to discuss additional updates to the Purdue information request list (based on results of review by G. Little); and (0.1) created initial draft of email to submit updated information request list to KPMG US.	0.2	\$	380	\$ 76.00
Arpit Desai	01/06/20	(0.1) Meeting with A. Desai and M. Latham (both KPMG UK) to discuss additional updates to the Purdue information request list (based on results of review by G. Little); and (0.1) senior manager review of draft email to US to submit copy of updated information request list prior to sending to KPMG US.	0.2	\$	750	\$ 150.00
Isaac Hirsch	01/06/20	Conference with I. Hirsch, M. Land and P. DiMatteo (all KPMG) to discuss and review information requests and workplan for purposes of identifying Canadian-specific components of the workplan and IRL.	0.4	\$	819	\$ 327.60
Michael Land	01/06/20	Conference with I. Hirsch, M. Land and P. DiMatteo (all KPMG) to discuss and review information requests and workplan for purposes of identifying Canadian-specific components of the workplan and IRL.	0.4	\$	534	\$ 213.60

KPMG LLP Monthly Fee Statement Page 11 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/U/4Fee68Application Pg 15 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Pete DiMatteo	01/06/20	Conference with I. Hirsch, M. Land and P. DiMatteo (all KPMG) to discuss and review information requests and workplan for purposes of identifying Canadian-specific components of the workplan and IRL.	0.4	\$	650	\$ 260.00
Mark Hoffenberg	01/06/20	Performed Principal Washington Nation Tax review of review of draft workplan related to Purdue Pharma bankruptcy tax consulting services.	0.4	\$	980	\$ 392.00
Pete DiMatteo	01/06/20	Conference with T. Giordano and P. DiMatteo (both KPMG) to discuss the creation of a global organization chart for purposes of future planning and tax cost modeling	0.5	\$	650	\$ 325.00
Thomas Giordano	01/06/20	Conference with T. Giordano and P. DiMatteo (both KPMG) to discuss the creation of a global organization chart for purposes of future planning and tax cost modeling	0.5	\$	350	\$ 175.00
Arpit Desai	01/06/20	Performed senior manager review and concurrently suggest additions to the updated Purdue information request list - prepared by M. Latham (KPMG UK Associate)	0.5	\$	750	\$ 375.00
Gavin Little	01/06/20	Senior manager review of updates to the Purdue Pharma information request list - prepared by A. Desai and M. Latham (both KPMG UK) and concurrently updated as needed.	0.5	\$	985	\$ 492.50
Madeleine Latham	01/06/20	Updated the Purdue Pharma information request list (from a UK tax perspective) based on review comments from A. Desai (KPMG UK)	0.5	\$	380	\$ 190.00
Casey Nunez	01/06/20	Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates.	0.6	\$	744	\$ 446.40
Howard Steinberg	01/06/20	Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates.	0.6	\$	856	\$ 513.60
Isaac Hirsch	01/06/20	Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates.	0.6	\$	819	\$ 491.40

KPMG LLP Monthly Fee Statement Page 12 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/UsFee8Application Pg 16 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate		Amount
Mark Hoffenberg	01/06/20	Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates.	0.6	\$ 98	\$	588.00
Ashley Armfield	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 53	4 \$	320.40
Casey Nunez	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 74	4 \$	446.40
Dawn Krishnamurthy	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 69	5 \$	417.00
Devon Rowles	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 35	\$	210.00
Isaac Hirsch	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 81	9 \$	491.40
Jess Commisso	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 35	\$	210.00
Michael Land	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$ 53	4 \$	320.40

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/16Fefe8Application Pg 17 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	ŀ	Rate	Amount
Sam Tyler	01/06/20	Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.	0.6	\$	743	\$ 445.80
Casey Nunez	01/06/20	Senior manager review of workplan updated with 4 foreign jurisdictions	0.7	\$	744	\$ 520.80
Arpit Desai	01/06/20	Discussion with A. Desai, G. Little and M. Latham (all KPMG UK) on the status of the project and items to include in the information request list following separate calls with the KPMG US team.	0.8	\$	750	\$ 600.00
Gavin Little	01/06/20	Discussion with A. Desai, G. Little and M. Latham (all KPMG UK) on the status of the project and items to include in the information request list following separate calls with the KPMG US team.	0.8	\$	985	\$ 788.00
Madeleine Latham	01/06/20	Discussion with A. Desai, G. Little and M. Latham (all KPMG UK) on the status of the project and items to include in the information request list following separate calls with the KPMG US team.	0.8	\$	380	\$ 304.00
Thomas Giordano	01/06/20	Completed review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage - as began earlier in the day.	0.9	\$	350	\$ 315.00
Madeleine Latham	01/06/20	Researching Purdue companies in scope in order to prepare the information request list and communication with A Desai and G Little (both KPMG UK) regarding same (as needed).	0.9	\$	380	\$ 342.00
Isaac Hirsch	01/06/20	Review Norton Rose cash tax cost calculations for purposes of implementing test run of cash tax cost model	0.9	\$	819	\$ 737.10
Devon Rowles	01/06/20	Incorporation of designated portion of KPMG member firms work plan / information request list data into master file in preparation to provide to client.	1.3	\$	350	\$ 455.00
Dawn Krishnamurthy	01/06/20	(0.3) Manager review of KPMG Canadian member firm workplan along with suggested information request items. (1.1) Review magnitude of revenue by country for purposes of identifying key regions/jurisdictions.	1.4	\$	695	\$ 973.00

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/11/7Fee8Application Pg 18 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	01/06/20	Incorporation of assigned portion of KPMG member firms' work plans / information request lists into master file in preparation to provide to client.	1.8	\$ 350	\$ 630.00
Pete DiMatteo	01/06/20	Draft template for organizational entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning	2.2	\$ 650	\$ 1,430.00
Jess Commisso	01/06/20	Updated KPMG shared site to include documentation provided by client as of 1/6/2020 to facilitate tax analysis.	2.2	\$ 350	\$ 770.00
Michael Land	01/06/20	Review and concurrently compile preliminary workplan including related information request list (IRL) based on information received from KPMG Member Firms Australia / United Kingdom.	2.3	\$ 534	\$ 1,228.20
Ashley Armfield	01/06/20	Review of latest version of workplan in preparation to discuss with project team (same day)	2.7	\$ 534	\$ 1,441.80
Jess Commisso	01/06/20	Continue (from 1/3) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	2.8	\$ 350	\$ 980.00
Isaac Hirsch	01/06/20	Drafted details regarding logic related to the Purdue Pharma cash tax cost model.	2.9	\$ 819	\$ 2,375.10
Thomas Giordano	01/06/20	Began review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	01/06/20	Continue (same day) to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 350	\$ 1,365.00

KPMG LLP Monthly Fee Statement Page 15 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/198Fee68Application Pg 19 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Carlotta Bertu	01/07/20	Perform Senior Associate initial review of Purdue Pharma available documents in KPMG Central (Shared Site) with regards to request for analysis to be performed for Purdue Pharma.	0.5	\$	640	\$ 320.00
Lorenzo Bellavite	01/07/20	Performed initial review, from Italian tax Partner perspective, of Purdue Pharma available documents in KPMG Central (Shared Site) with regards to request for analysis to be performed for Purdue Pharma.	0.5	\$	985	\$ 492.50
Pete DiMatteo	01/07/20	Conference with T. Giordano and P. DiMatteo (both KPMG) regarding entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning	0.7	\$	650	\$ 455.00
Thomas Giordano	01/07/20	Conference with T. Giordano and P. DiMatteo (both KPMG) regarding entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning	0.7	\$	350	\$ 245.00
Thomas Giordano	01/07/20	Continue, same day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	0.8	\$	350	\$ 280.00
Michael Land	01/07/20	Review of preliminary workplan along with information request list for purposes of project strategy	1.1	\$	534	\$ 587.40
Devon Rowles	01/07/20	Updating current version of Purdue information request list to reflect all information necessary to complete the current drafted workplan.	1.2	\$	350	\$ 420.00
Jess Commisso	01/07/20	Continue (from earlier in the day) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	1.4	\$	350	\$ 490.00
Isaac Hirsch	01/07/20	Managing Director review of current draft of entity list (prepared by T. Giordano and P. DiMatteo - KPMG) compiled from virtual data room for purposes of analyzing the potential cash tax consequences of entity/asset sales	1.6	\$	819	\$ 1,310.40

KPMG LLP Monthly Fee Statement Page 16 of 82

191293838041941shl D 000089350-EiledFi0280033206/210nteEntel028003320612502690274:2181ainEtatibitment Copy of KPMG First MoPtth 19/9Fee68Application Pg 20 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Jess Commisso	01/07/20	Updated Orion (KPMG share site) to include additional provided by client documentation as of 1/7/2020; (0.4) Updated working group list of broader KPMG team for newest addition of team members pursuant to providing contact information of all engagement participants to internal / external parties; (.6) Updated KPMG share site to include additional KPMG team members to facilitate review of provided by client documentation.	1.8	\$	350	\$ 630.00
Casey Nunez	01/07/20	Senior manager review of complete draft of workplan included first tier foreign country tax services as requested by client	2.1	\$	744	\$ 1,562.40
Isaac Hirsch	01/07/20	Continue (from 1/6) to draft details regarding logic related to Purdue Pharma cash tax cost model	2.4	\$	819	\$ 1,965.60
Dawn Krishnamurthy	01/07/20	(1.1) Perform Manager review of updated global workplan; (1.6) Manager review of updated global information request list including member firms' requests.	2.7	\$	695	\$ 1,876.50
Dawn Krishnamurthy	01/07/20	Performed analysis regarding Purdue and Mundipharma structure including current status of bankruptcy, ownership, legal claims and global presence - for purposes of identifying and gaining insight regarding key areas of focus (work performed concurrently).	2.8	\$	695	\$ 1,946.00
Isaac Hirsch	01/07/20	Implement test run of cash tax cost model (for purposes of analyzing the potential cash tax consequences of entity/asset sales) with respect to sale of Switzerland stock or assets	3.2	\$	819	\$ 2,620.80
Devon Rowles	01/07/20	Continued (from 12/31) to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.	3.3	\$	350	\$ 1,155.00
Ashley Armfield	01/07/20	Outlined inputs that need to be included in cash tax model based on the current version of the workplan as well as additional considerations based on the group's structure.	3.8	\$	534	\$ 2,029.20
Jess Commisso	01/07/20	Continue (from 1/6) review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00

KPMG LLP Monthly Fee Statement Page 17 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth ByOFee68Application Pg 21 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rat	e	Amount
Thomas Giordano	01/07/20	Continue, from 1/6, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 3.	50	\$ 1,365.00
Thomas Giordano	01/07/20	Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 3.	50	\$ 1,365.00
Andy Farinich	01/08/20	Call with A. Farinich and P. DiMatteo (both KPMG) regarding the formation of / revisions to an entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning	0.3	\$ 53	34	\$ 160.20
Pete DiMatteo	01/08/20	Call with A. Farinich and P. DiMatteo (both KPMG) regarding the formation of / revisions to an entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning	0.3	\$ 6	50	\$ 195.00
Aroen Rambhadjan	01/08/20	Call with A. Rambhadjan, K. van Meel and L. van der Veen (all KPMG Netherlands) to discuss the Purdue Pharma companies resident in the Netherlands; K. van Meel and M. de Kleermaeker provided background on the activities of the Purdue Pharma legal entities located in the Netherlands.	0.5	\$ 98	35	\$ 492.50
Kees van Meel	01/08/20	Call with A. Rambhadjan, K. van Meel and L. van der Veen (all KPMG Netherlands) to discuss the Purdue Pharma companies resident in the Netherlands; K. van Meel and M. de Kleermaeker provided background on the activities of the Purdue Pharma legal entities located in the Netherlands.	0.5	\$ 7.	57	\$ 378.50
Lukas van der Veen	01/08/20	Call with A. Rambhadjan, K. van Meel and L. van der Veen (all KPMG Netherlands) to discuss the Purdue Pharma companies resident in the Netherlands; K. van Meel and M. de Kleermaeker provided background on the activities of the Purdue Pharma legal entities located in the Netherlands.	0.5	\$ 73	30	\$ 365.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBylFefe8Application Pg 22 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Ra	:e	Amount
Pete DiMatteo	01/08/20	Conference with T. Giordano and P. DiMatteo (both KPMG) regarding research assignment to determine entitlement to a tax deduction upon the payment of a legal settlement.	0.5	\$ 6	50	\$ 325.00
Thomas Giordano	01/08/20	Conference with T. Giordano and P. DiMatteo (both KPMG) regarding research assignment to determine entitlement to a tax deduction upon the payment of a legal settlement.	0.5	\$ 3	50	\$ 175.00
Anja Poesl	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 7	50	\$ 375.00
Christian Schmid	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 9	85	\$ 492.50
Philipp Reer	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 7	65	\$ 382.50
Thomas Heubach	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 7	50	\$ 375.00
Lukas van der Veen	01/08/20	Manager review of draft document named Preliminary Analysis Sale of the Netherlands prepared by Norton Rose Fulbright, dated November 14, 2019 with focus on legal structure	0.8	\$ 7	30	\$ 584.00
Aroen Rambhadjan	01/08/20	Partner review of draft document "Preliminary Analysis Sale of the Netherlands" prepared by Norton Rose Fulbright, dated November 14, 2019 with focus on Purdue Pharma legal structure.	0.8	\$ 9	85	\$ 788.00
Michael Land	01/08/20	(0.3) Review of latest version of workplan and information request list to determine next steps related to bankruptcy tax consulting project; (0.6) Communication to coordinate with KPMG member firm (Netherlands) regarding administration for the anti-money laundering regime	0.9	\$ 5	34	\$ 480.60
Christian Schmid	01/08/20	Participated in kick-off meeting with T. Heubach and C. Schmid (both KPMG Germany) to discuss documentation received to date, teaming with KPMG US and next steps related to Purdue Pharma tax consulting project.	1.0	\$ 9	85	\$ 985.00

KPMG LLP Monthly Fee Statement Page 19 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By2Fee68Application Pg 23 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Thomas Heubach	01/08/20	Participated in kick-off meeting with T. Heubach and C. Schmid (both KPMG Germany) to discuss documentation received to date, teaming with KPMG US and next steps related to Purdue Pharma tax consulting project.	1.0	\$	750	\$ 750.00
Philipp Reer	01/08/20	Review of Purdue Pharma documentation (from German tax perspective) provided in the SharePoint as of 1/8/2020.	1.0	\$	765	\$ 765.00
Ashley Armfield	01/08/20	Revised project work plan in preparation to be circulated to the client and Purdue Pharma bankers - Per KPMG management request	1.1	\$	534	\$ 587.40
Thomas Giordano	01/08/20	Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	1.3	\$	350	\$ 455.00
Jess Commisso	01/08/20	Continued, from earlier in the day, review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	1.3	\$	350	\$ 455.00
Isaac Hirsch	01/08/20	(0.4) Communication via email with C. Nunez (KPMG) regarding analysis of ownership of Independent Affiliated Company for purposes of European tax analysis; (0.7) continue analysis of potential cash tax cost of settlement for purposes of preparing cash tax model; (0.3) Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement	1.4	\$	819	\$ 1,146.60
Devon Rowles	01/08/20	Continue, from previous day, to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.	1.6	\$	350	\$ 560.00
Thomas Giordano	01/08/20	Performed research to determine entitlement to a tax deduction for settlement payments	1.8	\$	350	\$ 630.00
Devon Rowles	01/08/20	Began to create a structure deck for the drafted term sheet to illustrate the sale of the Mundipharma entities	1.9	\$	350	\$ 665.00
Jess Commisso	01/08/20	Began to build out cash tax model pursuant to asset versus stock sale of Mundipharma entities.	2.2	\$	350	\$ 770.00

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Dawn Krishnamurthy	01/08/20	Review of data room documentation as of 1/8/2020 - for purposes of identifying potential Purdue Pharma tax issues	2.3	\$	695	\$ 1,598.50
Andy Farinich	01/08/20	Continued (same day) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	2.5	\$	534	\$ 1,335.00
Ashley Armfield	01/08/20	Meeting with A. Armfield and J. Commisso (both KPMG) for preliminary discussion related to Purdue cash tax model, focusing on set up, detail inclusion, scenario breakdown, and the end deliverable goal.	2.9	\$	534	\$ 1,548.60
Jess Commisso	01/08/20	Meeting with A. Armfield and J. Commisso (both KPMG) for preliminary discussion related to Purdue cash tax model, focusing on set up, detail inclusion, scenario breakdown, and the end deliverable goal.	2.9	\$	350	\$ 1,015.00
Ashley Armfield	01/08/20	Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy	3.1	\$	534	\$ 1,655.40
Dawn Krishnamurthy	01/08/20	Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy	3.1	\$	695	\$ 2,154.50
Michael Land	01/08/20	Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy	3.1	\$	534	\$ 1,655.40
Pete DiMatteo	01/08/20	Perform analysis regarding entitlement to potential tax deductions (including sections 162 and 165) arising from settlement payments made by Purdue and/or its owners under alternate scenarios (e.g., payments from trusts and/or partnerships).	3.4	\$	650	\$ 2,210.00

KPMG LLP Monthly Fee Statement Page 21 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBy4Fefe8Application Pg 25 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Andy Farinich	01/08/20	Began to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$	534	\$ 2,082.60
Jess Commisso	01/08/20	Continue (from 1/7) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/08/20	Continue, from 1/7, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$	350	\$ 1,365.00
Isaac Hirsch	01/09/20	Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement	0.5	\$	819	\$ 409.50
Michael Land	01/09/20	Meeting with D. Rowles (KPMG) to review the Purdue Pharma structure deck (for the term sheet) and concurrently discuss possible revisions	0.6	\$	534	\$ 320.40
Devon Rowles	01/09/20	Meeting with M. Land (KPMG) to review the Purdue Pharma structure deck (for the term sheet) and concurrently discuss possible revisions	0.6	\$	350	\$ 210.00
Andy Farinich	01/09/20	Continued (from earlier in the day) to review designated Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; Note : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	0.7	\$	534	\$ 373.80

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth BySFefe8Application Pg 26 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Jess Commisso	01/09/20	(0.4) Updated KPMG share site to include documentation provided by client as of 1/9/2020 - to facilitate tax analysis of same; (0.4): Review of new documentation uploaded to the data room by the client to circulate to KPMG project team.	0.8	\$	350	\$ 280.00
Casey Nunez	01/09/20	Review of current documentation in data room for purposes of building the cash tax model	0.8	\$	744	\$ 595.20
Anja Poesl	01/09/20	Performed initial review documents provided on SharePoint for Germany related to various Purdue Pharma entities (Verwaltungsgesellschaft GmbH, Krugmann GmbH, Mundichemie GmbH, Mundipharma Biologics GmbH, Mundipharma Deutschland GmbH und Co. KG, Mundipharma GmbH, Mundipharma Medical GmbH, Mundipharma Research GmbH & Co. KG, Munidpharma Research Verwaltungs GmbH) to gain overview regarding the information available to perform	1.0	\$	750	\$ 750.00
Thomas Giordano	01/09/20	analysis. Continued, from 1/8, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	1.5	\$	350	\$ 525.00
Jess Commisso	01/09/20	Created assigned portion of overall jurisdiction prioritization for Mundipharma entities, based on profit & loss information provided by the client, pursuant to the engagement of additional KPMG member firms.	1.6	\$	350	\$ 560.00
Lukas van der Veen	01/09/20	Performed analysis related to potential non-resident taxation issue if Dutch resident Cooperative would become the Master Holding company for companies located outside the United States.	1.8	\$	730	\$ 1,314.00
Howard Steinberg	01/09/20	Partner review of proposed workplan for purposes of facilitating a discussion with respect to tax scope	2.0	\$	856	\$ 1,712.00
Dawn Krishnamurthy	01/09/20	0.6 Review most recent round of updates to workplan to reflect evolving understanding of tax profile of high priority jurisdictions; 1.4 Review of data room documentation as of 1/9/2020 - for purpose of identifying areas of focus for workplan.	2.0	\$	695	\$ 1,390.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth 18/6Fee68Application Pg 27 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	Rate	Amount
Devon Rowles	01/09/20	Began to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms.	2.1	\$	350	\$ 735.00
Devon Rowles	01/09/20	Continue (from 1/8) creating a structure deck for the drafted term sheet to illustrate the sale of the Mundipharma entities	2.1	\$	350	\$ 735.00
Thomas Giordano	01/09/20	Performed research to determine entitlement to a tax deduction for settlement payments	2.5	\$	350	\$ 875.00
Thomas Giordano	01/09/20	Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	2.8	\$	350	\$ 980.00
Ashley Armfield	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$	534	\$ 1,655.40
Casey Nunez	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$	744	\$ 2,306.40
Dawn Krishnamurthy	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$	695	\$ 2,154.50
Michael Land	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$	534	\$ 1,655.40
Pete DiMatteo	01/09/20	Continue (from previous day) to perform analysis regarding entitlement to potential tax deductions (including sections 162 and 165) arising from settlement payments made by Purdue and/or its owners under alternate scenarios (e.g., payments from trusts and/or partnerships).	3.2	\$	650	\$ 2,080.00

KPMG LLP Monthly Fee Statement Page 24 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth 1877Fore8Application Pg 28 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Andy Farinich	01/09/20	Continue (from 1/8) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$	534	\$ 2,082.60
Andy Farinich	01/09/20	Continued (same day) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$	534	\$ 2,082.60
Carlotta Bertu	01/10/20	Reviewed KPMG Central (Shared Site) to extract new Purdue Pharma documentation available as of 1/10/2020.	0.1	\$	640	\$ 64.00
Sonia Stricker	01/10/20	Communication via email with J. Commisso (KPMG US) regarding go forward procedures to analyze Purdue Pharma documentation for use in German tax analysis.	0.2	\$	380	\$ 76.00
Thomas Heubach	01/10/20	Communication via email with J. Commisso (KPMG US) regarding go forward procedures to analyze Purdue Pharma documentation for use in German tax analysis.	0.2	\$	750	\$ 150.00
Jess Commisso	01/10/20	Additional updates to KPMG Share site to include additional KPMG team members to allow usage of provided by client documentation for tax analysis.	0.4	\$	350	\$ 140.00
Ashley Armfield	01/10/20	Review of term sheet pursuant to gaining insight regarding the proposed formation of / payments to the public trust for purposes of cash tax modeling.	0.8	\$	534	\$ 427.20
Thomas Heubach	01/10/20	Senior Manager review of draft list that will be used to collect information made available through the SharePoint (organizational structure and financial statements).	0.8	\$	750	\$ 600.00
Sonia Stricker	01/10/20	Analyzed the corporate structure of Purdue Pharma in Germany with focus on relevant shareholder chains, number of legal entities, legal forms.	1.0	\$	380	\$ 380.00

KPMG LLP Monthly Fee Statement Page 25 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth 18/8 Feetes Application Pg 29 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	ŀ	Rate	Amount
Thomas Heubach	01/10/20	Senior Manager review of analysis executed by S. Stricker (KPMG Germany) on the corporate structure of Purdue Pharma in Germany related to relevant shareholder chains, number of legal entities, legal forms.	1.0	\$	750	\$ 750.00
Thomas Giordano	01/10/20	Continued, from 1/9, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	1.2	\$	350	\$ 420.00
Howard Steinberg	01/10/20	Partner review of virtual data room information received to date for purposes of gaining insight regarding tax posture	1.4	\$	856	\$ 1,198.40
Andy Farinich	01/10/20	Continued (from 1/9) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage (1.2); and drafted email to P. DiMatteo (KPMG) to provide copy of same for Manager review (.2)"	1.4	\$	534	\$ 747.60
Isaac Hirsch	01/10/20	(0.5) Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement; (1.2) Perform additional review of Norton rose calculations for purposes migrating same to KPMG cash tax model	1.7	\$	819	\$ 1,392.30
Dawn Krishnamurthy	01/10/20	0.4 Communication via email to coordinate with KPMG Netherlands team (A. DeHaas) regarding information request list items; 1.2 Manager review of latest round of updates to workplan along with related information request list; 0.2 communication via email with A. Armfield, C. Nunez and M. Land (all KPMG) regarding updates related to structure deck and information requests as of 1/10.	1.8	\$	695	\$ 1,251.00
Michael Land	01/10/20	Review of sell side diligence report for purposes of gaining insight regarding the Purdue company's tax profile	1.8	\$	534	\$ 961.20

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By9Fefe8Application Pg 30 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Pete DiMatteo	01/10/20	Review of Purdue Pharma organization documentation to assist in creating global organization charts to ultimately assist in modeling / planning related to same.	2.1	\$	650	\$ 1,365.00
Pete DiMatteo	01/10/20	Continued (from 1/9) to perform analysis regarding permissibility of settlement payment deductions with regards to Purdue Pharma matter.	2.2	\$	650	\$ 1,430.00
Jess Commisso	01/10/20	Continue (from previous day) to create assigned portion of overall jurisdiction prioritization for Mundipharma entities, based on profit & loss information provided by the client, pursuant to the engagement of additional KPMG member firms.	2.3	\$	350	\$ 805.00
Sonia Stricker	01/10/20	Preparation of a list to collect information made available through the SharePoint (organizational structure / financial statements).	2.3	\$	380	\$ 874.00
Devon Rowles	01/10/20	(2.3) Continued (same day) to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms; (.3) Update to the information request list and current workplan with regards to review comments received from D. Krishnamurthy (KPMG) as of 1/10/2020.	2.6	\$	350	\$ 910.00
Andy Farinich	01/10/20	Reviewed additional Purdue Pharma organizational structure documentation provided by client, as of 1/10/2020, and concurrently updated excel file to include same.	2.8	\$	534	\$ 1,495.20
Thomas Giordano	01/10/20	Continued (from 1/9) to perform research to determine entitlement to a tax deduction for settlement payments	3.0	\$	350	\$ 1,050.00
Ashley Armfield	01/10/20	Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.	3.6	\$	534	\$ 1,922.40
Casey Nunez	01/10/20	Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.	3.6	\$	744	\$ 2,678.40
Isaac Hirsch	01/10/20	Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.	3.6	\$	819	\$ 2,948.40
Michael Land	01/10/20	Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.	3.6	\$	534	\$ 1,922.40

KPMG LLP Monthly Fee Statement Page 27 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Jess Commisso	01/10/20	Continue (same day) to create assigned portion of overall jurisdiction prioritization for Mundipharma entities, based on profit & loss information provided by the client, pursuant to the engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00
Devon Rowles	01/10/20	Continued, from earlier in the day, to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms.	3.9	\$	350	\$ 1,365.00
Dawn Krishnamurthy	01/11/20	Review of Norton Rose data room information for purposes of gaining insight regarding structure and tax profile of Mundipharma entities.	2.1	\$	695	\$ 1,459.50
Dawn Krishnamurthy	01/11/20	1.1 Review of tax profile of Purdue and Mundipharma entities for the purpose of gaining insight regarding the structure and identifying open items/questions; 2.3 Continue review (same day) of Purdue and Mundipharma structure charts and information provided in the data room for purposes of identifying issues and preliminary questions	3.4	\$	695	\$ 2,363.00
Dawn Krishnamurthy	01/12/20	1.3 Review of Norton Rose Independent Affiliated Company (IAC) Tax Meeting Combined file with focus on calculations/trust structure; 1.0 Review of rules with respect to taxation of distributions between trusts.	2.3	\$	695	\$ 1,598.50
Andy Farinich	01/13/20	Conference with P. DiMatteo and A. Farinich (both KPMG) to discuss creating a visual depiction of the Norton Rose Calculations on the organizational charts provided by client	0.3	\$	534	\$ 160.20
Pete DiMatteo	01/13/20	Conference with P. DiMatteo and A. Farinich (both KPMG) to discuss creating a visual depiction of the Norton Rose Calculations on the organizational charts provided by client	0.3	\$	650	\$ 195.00
Oron Zeevi	01/13/20	Discussion with A. Eytan (KPMG) regarding the Purdue Pharma structure in Israel with regards to tax analysis to be performed	0.3	\$	450	\$ 135.00
Arik Eytan	01/13/20	Discussion with O. Zeevi (KPMG) regarding the Purdue Pharma structure in Israel with regards to tax analysis to be performed	0.3	\$	555	\$ 166.50

KPMG LLP Monthly Fee Statement Page 28 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBylFefe8Application Pg 32 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours]	Rate	Amount
Thomas Giordano	01/13/20	Continued, from 1/10, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	0.4	\$	350	\$ 140.00
Isaac Hirsch	01/13/20	Managing Director review of updated IRL along with current version of the Purdue cash tax model - with regards to comments received from M&A team	0.5	\$	819	\$ 409.50
Jess Commisso	01/13/20	Continue (same day) to update the cash tax model to include assumptions / sale analysis data provided by the client to develop disposition strategies of Mundipharma entities.	0.6	\$	350	\$ 210.00
Casey Nunez	01/13/20	Senior Manager Review of latest round of updates to Purdue information request list as of 1/13/2020.	0.7	\$	744	\$ 520.80
Thomas Giordano	01/13/20	0.3 Reviewed client provided computations associated with various distributions between entities in global organization structure; 0.5 depicted various distributions between entities in global organization structure based on client provided computations / organization structures.	0.8	\$	350	\$ 280.00
Oron Zeevi	01/13/20	Performed initial review of Purdue Pharma's structure along with related financial statements	0.8	\$	450	\$ 360.00
Pete DiMatteo	01/13/20	Review Norton Rose computations to determine plan to map cash flows on Norton Rose org charts for ease of review.	0.8	\$	650	\$ 520.00
Ashley Armfield	01/13/20	Revised draft of email to KPMG UK team relating to structuring of the disposition of Mundipharma assets and distribution of proceeds at the trust/beneficiary level pursuant to identifying applicable taxes for structuring per manager review comments received from D. Krishnamurthy (KPMG)	0.8	\$	534	\$ 427.20
Devon Rowles	01/13/20	Meeting with M. Land (KPMG) and D. Rowles (KPMG) to discuss research into deductibility of settlement payment	1.1	\$	350	\$ 385.00
Michael Land	01/13/20	Meeting with M. Land (KPMG) and D. Rowles (KPMG) to discuss research into deductibility of settlement payment	1.1	\$	534	\$ 587.40

KPMG LLP Monthly Fee Statement Page 29 of 82

19123230494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBy2Fee8Application Pg 33 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Andy Farinich	01/13/20	Continue, from earlier in the day, to create a visual representation of the Norton Rose Calculations and concurrently incorporated cash-flows on the organizational charts provided by client; Note: this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario.	1.2	\$	534	\$ 640.80
Andy Farinich	01/13/20	Continued (from 1/10) to review organizational structure materials provided by client in order to finalize the excel workbook created (.7); drafted email to send to P. DiMatteo (KPMG) to review same with regards to the use of this data in the creation of an overall organizational structure chart (0.3); Drafted additional email to P. DiMatteo (KPMG) explaining the updates that were made to the excel file (with organization structure data) (0.2).	1.2	\$	534	\$ 640.80
Ashley Armfield	01/13/20	Continued (same day) Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, and next steps related to inputs and disposition scenario for Switzerland Mundipharma MEA GmbH.	1.4	\$	534	\$ 747.60
Jess Commisso	01/13/20	Continued (same day) Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, and next steps related to inputs and disposition scenario for Switzerland Mundipharma MEA GmbH.	1.4	\$	350	\$ 490.00
Thomas Heubach	01/13/20	Performed analysis over 9 entities (screened on same day) with focus on determining how the entities are treated for tax purposes, i.e. taxed as a corporation or flow-through partnership based on the financial statements provided.	1.5	\$	750	\$ 1,125.00
Christian Schmid	01/13/20	Initial Partner review of Purdue Pharma documentation provided to date with regards to German tax analysis.	1.6	\$	985	\$ 1,576.00
Howard Steinberg	01/13/20	Performed Partner review of proposed information request list with regards to high priority jurisdictions	2.0	\$	856	\$ 1,712.00

KPMG LLP Monthly Fee Statement Page 30 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBy3Fee8Application Pg 34 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Devon Rowles	01/13/20	Begin review of documentation (case law, treasury regulations, etc.) to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo regarding deductibility of restitute payments for the debtors	2.1	\$	350	\$ 735.00
Ashley Armfield	01/13/20	Developing US cash tax calculation for Switzerland Mundipharma MEA GmbH pursuant to preparing a draft cash tax model related to the disposition of certain entities.	2.5	\$	534	\$ 1,335.00
Devon Rowles	01/13/20	(2.7) Update jurisdiction prioritization file to include a master summary pursuant to engaging additional KPMG member firms.	2.7	\$	350	\$ 945.00
Thomas Heubach	01/13/20	Screening of the individual / consolidated audited financial statements (FS) under local GAAP for the financial years 2016, 2017 and 2018 for the following legal entities unless stated otherwise: 1. Germany Verwaltungsgesellschaft GmbH (0.4) 2. Krugmann GmbH (0.4) 3. Mundichemie GmbH (0.4) 4. Mundipharma Deutschland GmbH & Co. KG (0.4) 5. Mundipharma GmbH (0.4) 6. Mundipharma Medical GmbH (0.4) 7. Mundipharma Research GmbH & Co. KG (0.4) 8. Mundipharma Research Verwaltungsgesellschaft - (only FS 2016 provided) (0.2)	3.0	\$	750	\$ 2,250.00
Dawn Krishnamurthy	01/13/20	0.4 Manager review of updates to information request list (IRL) as of 1/13/2020 that incorporates KPMG member firm input. 0.6 Manager review of email to the UK member firm regarding tax consequences of distribution from UK entity to US entity; 2.1 review of Project Malta reports for tax relevant information.	3.1	\$	695	\$ 2,154.50
Ashley Armfield	01/13/20	1.4 Researching the deductibility of restitution payments pursuant to writing a KPMG opinion; 0.4 drafting email to D. Rowles (KPMG) relating to drafting memo of deductibility of restitution payment (including sources); 1.4 Drafting email to KPMG UK team relating to structuring of the disposition of Mundipharma assets and distribution of proceeds at the trust/beneficiary level pursuant to identifying applicable taxes for structuring.	3.2	\$	534	\$ 1,708.80

KPMG LLP Monthly Fee Statement Page 31 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBy4Fefe8Application Pg 35 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	01/13/20	(2.1) Reviewed documentation on the Prime Clerk docket for tax relevant information related to financial position, restitution payments, etc. (1.3) updating the term sheet structure deck to reflect additional comments received from M. Land (KPMG) in preparation to circulate to the entire KPMG project team	3.4	\$ 350	\$ 1,190.00
Dawn Krishnamurthy	01/13/20	1.2 Review of financial statements for high priority jurisdictions for tax exposure information; 0.8 Manager review of PowerPoint deck depiction of proposed settlement prepared by D. Rowles (KPMG). 1.4 Review of Project Malta reports with focus on tax exposures	3.4	\$ 695	\$ 2,363.00
Michael Land	01/13/20	Review of sell side diligence report for purposes of gaining insight regarding the Mundipharma entities.	3.4	\$ 534	\$ 1,815.60
Sonia Stricker	01/13/20	Compiled initial data related to Purdue Key Financials (sales, profit, balance sheet total and employees) for entities 6 - 8 for years 2016-2018 and for entry 9 for year 2016	3.6	\$ 380	\$ 1,368.00
Pete DiMatteo	01/13/20	Began to review entity-specific organization charts to compile a global list (in excel) of numerous Purdue Pharma entities for purposes of creating a global organization chart.	3.8	\$ 650	\$ 2,470.00
Andy Farinich	01/13/20	Began creating a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; Note: this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario.	3.9	\$ 534	\$ 2,082.60
Thomas Giordano	01/13/20	Continue, from earlier in the day, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 350	\$ 1,365.00

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth BySFee68Application Pg 36 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Thomas Giordano	01/13/20	Continued, from same day, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$	350	\$ 1,365.00
Sonia Stricker	01/13/20	Extract and concurrently compile initial data related to Purdue Key Financials (sales, profit, balance sheet total and employees) for entities 1 - 5 for years 2016-2018.	3.9	\$	380	\$ 1,482.00
Ashley Armfield	01/13/20	Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, with specific regards to inputs / disposition scenarios for Switzerland Mundipharma MEA GmbH	3.9	\$	534	\$ 2,082.60
Jess Commisso	01/13/20	Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, with specific regards to inputs / disposition scenarios for Switzerland Mundipharma MEA GmbH	3.9	\$	350	\$ 1,365.00
Jess Commisso	01/13/20	Updated the cash tax model to include assumptions / sale analysis data provided by the client, as of 1/13/20, to develop disposition strategies of Mundipharma entities.	3.9	\$	350	\$ 1,365.00
Andy Farinich	01/14/20	Continued (same day) to create a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; Note: this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario.	0.3	\$	534	\$ 160.20
Oron Zeevi	01/14/20	Draft email to J. Commisso (KPMG) with respect to the Purdue Pharma structure and shareholders tax status	0.4	\$	450	\$ 180.00

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBy6Fee8Application Pg 37 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	!	Amount
Dawn Krishnamurthy	01/14/20	Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.	0.9	\$ 69	5 \$	625.50
Isaac Hirsch	01/14/20	Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.	0.9	\$ 81	9 \$	737.10
Michael Land	01/14/20	Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.	0.9	\$ 53	4 \$	480.60
Pete DiMatteo	01/14/20	Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.	0.9	\$ 65	0 \$	585.00
Ashley Armfield	01/14/20	Perform Senior associate review of research results prepared by D. Rowles (KPMG) on restitution deduction pursuant to drafting a restitution memo	0.9	\$ 53	4 \$	480.60
Devon Rowles	01/14/20	Continued, from earlier in the day, to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments	1.1	\$ 35	0 \$	385.00
Ashley Armfield	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow for Canada	1.1	\$ 53	4 \$	587.40
Michael Land	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow for Canada	1.1	\$ 53	4 \$	587.40
Pete DiMatteo	01/14/20	Review Norton Rose computational organization charts annotated by KPMG to depict cash flows from proposed asset and/or stock sales.	1.1	\$ 65	0 \$	715.00
Michael Land	01/14/20	Review of Project Malta (sell side diligence report) volume 2 for purposes of gaining insight regarding the foreign company structure and activities	1.1	\$ 53	4 \$	587.40
Pete DiMatteo	01/14/20	Continue (from 1/13) to review entity-specific organization charts to create an excel based global organization chart for purposes of generating global organization charts consisting of numerous Purdue Pharma entities	1.5	\$ 65	0 \$	975.00
Jess Commisso	01/14/20	Performed research on restitution deduction pursuant to the drafting a restitution memo.	1.8	\$ 35	0 \$	630.00
Ashley Armfield	01/14/20	Meeting with M. Land, A. Armfield and J. Commisso (all KPMG) to discuss latest version of Purdue cash tax model and next steps related to possible updates.	1.9	\$ 53	4 \$	1,014.60

KPMG LLP Monthly Fee Statement Page 34 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	Rate	Amount
Jess Commisso	01/14/20	Meeting with M. Land, A. Armfield and J. Commisso (all KPMG) to discuss latest version of Purdue cash tax model and next steps related to possible updates.	1.9	\$	350	\$ 665.00
Michael Land	01/14/20	Meeting with M. Land, A. Armfield and J. Commisso (all KPMG) to discuss latest version of Purdue cash tax model and next steps related to possible updates.	1.9	\$	534	\$ 1,014.60
Thomas Heubach	01/14/20	Performed analysis of Purdue structure for tax purposes, with specific regards to tracking down stand-alone taxed entities / tax grouping arrangements in place for income tax and VAT purposes, based on the financial statements provided.	2.0	\$	750	\$ 1,500.00
Dawn Krishnamurthy	01/14/20	1.8 Drafted Manager review comments related to term sheet summary in PowerPoint (prepared for purposes of gaining insight regarding tax consequences of initial proposed transaction); 0.4 Review of similar bankruptcy case with regards to the deductibility of payments to claimants with regards to Purdue Pharma case - to gain insight regarding treatment under facts for a similarly situated taxpayer.	2.2	\$	695	\$ 1,529.00
Ashley Armfield	01/14/20	Perform updates to model structure based on manager review comments (pursuant to cash tax model) with specific regards to inputs tab, sale analysis layout and coding.	2.3	\$	534	\$ 1,228.20
Devon Rowles	01/14/20	Continue (same day) to review case law, treasury regulations, etc. to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo	2.4	\$	350	\$ 840.00
Sonia Stricker	01/14/20	Compiled initial data on high-level facts / particularities / extraordinary transactions and arrangements (e.g. reorganizations, disposals, acquisitions, silent partnerships) out of the financial statements for entities 6 - 8 for years 2016 - 2018 and for entry 9 for year 2016.	2.5	\$	380	\$ 950.00
Thomas Heubach	01/14/20	Analyzed the size, business purpose and financial situation (profitability, materiality) of each Purdue legal entity (2016-2018) with focus on each entities' business model, risk profile and maintained functions (e.g. holding, operating or special purpose entity; financing, procurement or distribution functions, etc.; low-risk, medium-risk or high-risk, main entrepreneur, customer-contract risks, etc.)	2.8	\$	750	\$ 2,100.00
Sonia Stricker	01/14/20	Compiled initial data on high-level facts / particularities / extraordinary transactions and arrangements (e.g. reorganizations, disposals, acquisitions, silent partnerships) out of the financial statements for Purdue entities 1 - 5 for years 2016-2018.	3.0	\$	380	\$ 1,140.00

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By8Fee68Application Pg 39 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	ate	Amount
Dawn Krishnamurthy	01/14/20	Review of "Malta" report (a sell side diligence report) for purpose of identifying potential tax issues	3.3	\$	695	\$ 2,293.50
Dawn Krishnamurthy	01/14/20	2.2 Manager review of project team comments to information request list while concurrently cross checking against Norton Rose structure decks for purpose of finalizing information requests; 1.3 Performed Manager review of restitution payment research for purpose of gaining insight regarding tax treatment	3.5	\$	695	\$ 2,432.50
Jess Commisso	01/14/20	Additional updates to the Purdue cash tax model to include assumptions / sale analysis data provided by the client to develop disposition strategies of Mundipharma entities	3.9	\$	350	\$ 1,365.00
Andy Farinich	01/14/20	Continue (from earlier in the day) to create a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; Note: this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario.	3.9	\$	534	\$ 2,082.60
Thomas Giordano	01/14/20	Continue, from 1/13, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$	350	\$ 1,365.00
Devon Rowles	01/14/20	Continue, from previous day, to review case law, treasury regulations, etc. to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo	3.9	\$	350	\$ 1,365.00

191293838041941shl D 000089350-EiledFi0280033206/210nteEntel028003320612502690274:2181ainEtatribitment Copy of KPMG First MoPhth By9Fee68Application Pg 40 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours]	Rate	Amount
Andy Farinich	01/14/20	Continued (from 1/13) creating a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; Note: this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario.	3.9	\$	534	\$ 2,082.60
Jess Commisso	01/14/20	Mapping out sale calculations of Mundipharma MEA and Mundipharma DC BV with focus on where values are derived from / where clarification from client is necessary.	3.9	\$	350	\$ 1,365.00
Ashley Armfield	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to continue (from same day) discussions regarding preparation of cash tax model for purposes of project strategy and cash flow for Switzerland	3.9	\$	534	\$ 2,082.60
Michael Land	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to continue (from same day) discussions regarding preparation of cash tax model for purposes of project strategy and cash flow for Switzerland	3.9	\$	534	\$ 2,082.60
Ashley Armfield	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow on general inputs tabs	3.9	\$	534	\$ 2,082.60
Michael Land	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow on general inputs tabs	3.9	\$	534	\$ 2,082.60
Devon Rowles	01/14/20	Performed tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments	3.9	\$	350	\$ 1,365.00

KPMG LLP Monthly Fee Statement Page 37 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours]	Rate	Amount
Thomas Giordano	01/14/20	Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; Note: this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	4.1	\$	350	\$ 1,435.00
Karen Erickson	01/15/20	Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.	0.4	\$	690	\$ 276.00
Pete DiMatteo	01/15/20	Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.	0.4	\$	650	\$ 260.00
Thomas Giordano	01/15/20	Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.	0.4	\$	350	\$ 140.00
Devon Rowles	01/15/20	Continue - on same day - to analyze provided by client documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow - as began on same day.	0.6	\$	350	\$ 210.00
Devon Rowles	01/15/20	Continued, from earlier in the day, to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments.	0.6	\$	350	\$ 210.00
Pete DiMatteo	01/15/20	Continued (from 1/14) to review of entity-specific organization charts to create an excel based global organization chart for purposes of generating global organization charts consisting of numerous Purdue Pharma entities	1.1	\$	650	\$ 715.00
Ashley Armfield	01/15/20	Creating US Tax calculation tab in the cash tax model to calculate individual shareholder taxation for US federal income and state tax purposes (flowing from Foreign tax credits tab).	1.9	\$	534	\$ 1,014.60

KPMG LLP Monthly Fee Statement Page 38 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthNylFefe8Application Pg 42 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Sonia Stricker	01/15/20	Compiled information on tax profile, tax compliance status (years for which tax returns have been filed and assessed, open tax years, tax payments), tax audit status (tax years covered by the audit, open tax years) for entities 6 - 8 for years 2016 - 2018 and for entry 9 for year 2016 based on the financial statements provided.	2.0	\$	380	\$ 760.00
Dawn Krishnamurthy	01/15/20	2.2 Review of PLCONV_LEG_LR 10.12.19.xlsx, tax litigation file, Project Malta Reports, EY flowchart, Term Sheet, etc. (performed concurrently to cross-check information) in preparation for Norton Rose meeting.	2.2	\$	695	\$ 1,529.00
Jess Commisso	01/15/20	Continued (same day) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	2.4	\$	350	\$ 840.00
Sonia Stricker	01/15/20	Compiled information on tax profile, tax compliance status (years for which tax returns have been filed and assessed, open tax years, tax payments), tax audit status (tax years covered by the audit, open tax years) for entities 1 - 5 for years 2016 - 2018 based on the financial statements provided.	2.5	\$	380	\$ 950.00
Dawn Krishnamurthy	01/15/20	1.2 Manager review of draft Organization Listing compiled - with focus on Mundipharma structure; 1.4 Manager review of material jurisdiction calculations (including supporting information); 0.2 Manager review of draft email regarding deductibility of restitution payments	2.8	\$	695	\$ 1,946.00
Ashley Armfield	01/15/20	1.9 Updating cash tax model to include Mundipharma Singapore Holding Pte. Limited disposition scenario; 0.9 Updated cash tax model in preparation for manager review / external presentation.	2.8	\$	534	\$ 1,495.20
Casey Nunez	01/15/20	Finalized updates to initial information request list based on virtual data room review	2.8	\$	744	\$ 2,083.20
Dawn Krishnamurthy	01/15/20	Performed Manager review of Independent Affiliated Company (IAC) combined structure file	2.8	\$	695	\$ 1,946.00
Ashley Armfield	01/15/20	Updating foreign tax credits calculation tab in the cash tax model to serve as a baseline for future calculations pursuant to forecasting expected cash taxes.	2.8	\$	534	\$ 1,495.20
Ashley Armfield	01/15/20	1.7 Updating cash tax model to include Napp Pharmaceutical Holdings Limited disposition scenario; 1.2 Updating cash tax model to include Mundipharma Deutschland GmbH & Co. KG disposition scenario.	2.9	\$	534	\$ 1,548.60

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthly/2Fee68Application Pg 43 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Jess Commisso	01/15/20	Revised the cash tax model by including assumptions / updated Mundipharma entity data to develop disposition strategies of Mundipharma entities.	2.9	\$	350	\$ 1,015.00
Michael Land	01/15/20	2.4 Senior associate review of summary of deduction analysis under Code section 162 for purposes of gaining insight regarding the deductibility of settlement payments; 0.6 review of information request list / virtual data room documentation to determine if additional information was provided as of 1/15/2020; 0.2 Performed Senior Associate review of most recent round of assumptions for Purdue cash tax model as of 1/15/2020.	3.2	\$	534	\$ 1,708.80
Renay Gosen	01/15/20	Research section 170 charitable contribution deduction in relation to writing memo showing whether settlement payments to the public could be categorized as a "charitable contribution."	3.2	\$	350	\$ 1,120.00
Devon Rowles	01/15/20	Analyzed designated portion of provided by client documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow.	3.9	\$	350	\$ 1,365.00
Jess Commisso	01/15/20	Began to analyze assigned portion of provided by client (PBC) documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	3.9	\$	350	\$ 1,365.00
Devon Rowles	01/15/20	Continue (from previous day) to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments	3.9	\$	350	\$ 1,365.00
Jess Commisso	01/15/20	Continue, on same day, to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	3.9	\$	350	\$ 1,365.00
Jess Commisso	01/15/20	Continued (from earlier in the day) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	3.9	\$	350	\$ 1,365.00
Devon Rowles	01/15/20	Draft memo regarding the deductibility of restitution payments for a more-likely-than-not tax position.	3.9	\$	350	\$ 1,365.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthN/3Fefe8Application Pg 44 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	J	Rate	Amount
Michael Land	01/15/20	Meeting with M. Land and A. Armfield (KPMG) to discuss various cash tax inputs in relation to impact on overall cash tax model	3.9	\$	534	\$ 2,082.60
Ashley Armfield	01/15/20	Meeting with M. Land and A. Armfield (KPMG) to discuss various cash tax inputs in relation to impact on overall cash tax model	3.9	\$	534	\$ 2,082.60
Ashley Armfield	01/15/20	Meeting between M. Land and A. Armfield (both KPMG) to discuss foreign tax credits inputs to cash tax model	3.9	\$	534	\$ 2,082.60
Michael Land	01/15/20	Meeting between M. Land and A. Armfield (both KPMG) to discuss foreign tax credits inputs to cash tax model	3.9	\$	534	\$ 2,082.60
Casey Nunez	01/15/20	Meeting with H. Steinberg and C. Nunez (both KPMG) for purpose of clarifying and reducing information requests; this was a meeting reviewing, in detail, our workplan as well as the related information request list before they were to be sent to attorneys regarding numerous Purdue Pharma entities with focus on nine jurisdictions including: 1. Australia, 2. Canada, 3. China, 4. Germany, 5. Israel, 6. Italy, 7. Netherlands, 8. South Korea and 9. UK.	3.9	\$	744	\$ 2,901.60
Howard Steinberg	01/15/20	Meeting with H. Steinberg and C. Nunez (both KPMG) for purpose of clarifying and reducing information requests; this was a meeting reviewing, in detail, our workplan as well as the related information request list before they were to be sent to attorneys regarding numerous Purdue Pharma entities with focus on nine jurisdictions including: 1. Australia, 2. Canada, 3. China, 4. Germany, 5. Israel, 6. Italy, 7. Netherlands, 8. South Korea and 9. UK.	3.9	\$	856	\$ 3,338.40
Dawn Krishnamurthy	01/15/20	Meeting with H. Steinberg and C. Nunez (both KPMG) for purpose of clarifying and reducing information requests; this was a meeting reviewing, in detail, our workplan as well as the related information request list before they were to be sent to attorneys regarding numerous Purdue Pharma entities with focus on nine jurisdictions including: 1. Australia, 2. Canada, 3. China, 4. Germany, 5. Israel, 6. Italy, 7. Netherlands, 8. South Korea and 9. UK.	3.9	\$	695	\$ 2,710.50
Michael Land	01/15/20	Performed research regarding deduction of settlement payment for purposes of cash tax model.	3.9	\$	534	\$ 2,082.60
Devon Rowles	01/15/20	Review of additional documentation (case law, treasury regulations, etc.) to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo	3.9	\$	350	\$ 1,365.00
Dawn Krishnamurthy	01/16/20	Communication with I. Hirsch KPMG) regarding objectives related to Norton Rose meeting (on same day).	0.2	\$	695	\$ 139.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthNy4Fee8Application Pg 45 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Dawn Krishnamurthy	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$	695	\$ 208.50
Howard Steinberg	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$	856	\$ 256.80
Isaac Hirsch	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$	819	\$ 245.70
Mark Hoffenberg	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$	980	\$ 294.00
Sonia Stricker	01/16/20	Meeting with S. Stricker and T. Heubach (both KPMG) to update information request list based on data received to date and add additional required documents.	1.0	\$	380	\$ 380.00
Thomas Heubach	01/16/20		1.0	\$	750	\$ 750.00
Michael Land	01/16/20	0.3 Updates to Purdue cash tax model with regards to German foreign branch tax; 0.8 review of updated information request list received.	1.1	\$	534	\$ 587.40
Thomas Giordano	01/16/20	Continue (same day) to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law.	1.1	\$	350	\$ 385.00
Dawn Krishnamurthy	01/16/20	1.0 Review of data room documentation for purpose of gaining an understanding regarding tax exam/audit profile of Canada, China, Germany, Israel, Italy, Netherlands, South Korea, Switzerland, UK; 0.4 Review of Project Malta reports.	1.4	\$	695	\$ 973.00
Christian Schmid	01/16/20	Partner review of interim collection of data prepared by T. Heubach and S. Stricker (both KPMG Germany).	1.4	\$	985	\$ 1,379.00

KPMG LLP Monthly Fee Statement Page 42 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthNy5Fefe8Application Pg 46 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Dawn Krishnamurthy	01/16/20	Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model.	2.0	\$	695	\$ 1,390.00
Howard Steinberg	01/16/20	Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model.	2.0	\$	856	\$ 1,712.00
Isaac Hirsch	01/16/20	Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model.	2.0	\$	819	\$ 1,638.00
Mark Hoffenberg	01/16/20	Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model.	2.0	\$	980	\$ 1,960.00
Isaac Hirsch	01/16/20	Preparation for meeting with Norton Rose (on same day), including review of Norton Rose calculation (1.5), KPMG inprocess cash tax model (0.7), and Purdue organizational charts (0.4).	2.6	\$	819	\$ 2,129.40
Thomas Heubach	01/16/20	Review of interim collection of data prepared by S. Stricker (KPMG Germany) and reconcile concurrently with financial statements.	3.2	\$	750	\$ 2,400.00
Dawn Krishnamurthy	01/16/20	Performed analysis to compare calculations of asset versus stock scenarios in Norton Rose calculations in comparison to KPMG draft model.	3.3	\$	695	\$ 2,293.50
Devon Rowles	01/16/20	(2.2) Continued to analyze designated portion of provided by client (PBC) documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; (1.2) update the information request list to account for all provided by client information as of 1/16/2020.	3.4	\$	350	\$ 1,190.00

KPMG LLP Monthly Fee Statement

Page 43 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth14/6Fee68Application Pg 47 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Ashley Armfield	01/16/20	1.4 Senior associate review of priority jurisdiction file pursuant to providing information to team for client/banker meeting; 2.1 Senior associate review of KPMG review of Norton Rose calculation and concurrently noted outstanding items.	3.5	\$	534	\$ 1,869.00
Jess Commisso	01/16/20	Continue (from 1/15) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma	3.6	\$	350	\$ 1,260.00
Dawn Krishnamurthy	01/16/20	entities. 2.7 Continued review of tax profile by jurisdiction for purposes of identifying material jurisdictions; 1.2 Updates to information requests based on Norton Rose Meeting Notes	3.9	\$	695	\$ 2,710.50
Thomas Giordano	01/16/20	Began to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/17/20	Continued to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments - (as began on same day).	0.9	\$	350	\$ 315.00
Isaac Hirsch	01/17/20	Performed Managing Director review of review of IRM updates by D. Krishnamurthy (KPMG) and concurrently draft review comments	1.1	\$	819	\$ 900.90
Thomas Giordano	01/17/20	0.8 Continued, from previous day, to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law; 0.5 drafted outline of initial findings based on research performed to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law	1.3	\$	350	\$ 455.00
Michael Land	01/17/20	Review of cash tax model with regards to partnership waterfall allocations in the United Kingdom	1.3	\$	534	\$ 694.20
Pete DiMatteo	01/17/20	Performed analysis regarding mechanics of foreign tax credits for trusts/individuals for purposes of refining overall tax cost model	1.6	\$	650	\$ 1,040.00
Howard Steinberg	01/17/20	Performed Partner review of information request list updates related to high priority jurisdictions	1.7	\$	856	\$ 1,455.20
Dawn Krishnamurthy	01/17/20	1.1 Continued (from 1/16) review of data room documents for purpose of identifying most relevant jurisdictions from a tax perspective; 0.7 Updates to information request list based on information provided by Norton Rose with respect to Switzerland.	1.8	\$	695	\$ 1,251.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthly/Trefe8Application Pg 48 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	9	Amount
Jess Commisso	01/17/20	Review of documentation in virtual data room as of 1/17/2020 to determine if we need to request the client provided structure charts, trust documentation or partnership agreements pursuant to further diligence of Mundipharma entities.	2.8	\$ 35	50 \$	980.00
Casey Nunez	01/17/20	0.8 Senior manager review of updated information request list based on feedback from January 16th meeting with Norton Rose and Debevoise; 1.9 review of new Purdue Pharma documentation available in data room as of 1/17; 0.6 review of sell side diligence report for Project Malta.	3.3	\$ 74	14 \$	2,455.20
Dawn Krishnamurthy	01/17/20	Review of structure charts / financial statements to gain insight regarding tax impacts of potential sale scenarios in high priority jurisdictions.	3.3	\$ 69	95 \$	2,293.50
Thomas Giordano	01/17/20	Performed research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	3.9	\$ 35	50 \$	1,365.00
Howard Steinberg	01/18/20	Partner review of virtual data room information received as of 1/18/20 for purposes of determining relevant tax information available.	1.0	\$ 85	56 \$	856.00
Dawn Krishnamurthy	01/18/20	Continue, from earlier in the day, to review documentation in the Norton Rose data room for purpose of determining most significant jurisdictions/identifying areas of focus.	1.4	\$ 69	95 \$	973.00
Dawn Krishnamurthy	01/18/20	Review of information provided in the Norton Rose data room as of 1/18/20, including Project Malta reports, financial statements and litigation summaries with regards to updating the information request list.	2.8	\$ 69	95 \$	1,946.00
Dawn Krishnamurthy	01/18/20	Continued (same day) to review documents provided in data room as of 1/18/20 for purposes of updating / tailoring the information request list.	3.1	\$ 69	95 \$	2,154.50
Howard Steinberg	01/19/20	Perform Partner review of financial statement summary for purposes of gaining insight regarding tax posture	1.5	\$ 85	56 \$	1,284.00
Dawn Krishnamurthy	01/19/20	Review of financial statements provided in Norton Rose data room for purposes of updating information request list.	3.4	\$ 69	95 \$	2,363.00
Pete DiMatteo	01/20/20	Conference call with P. DiMatteo and T. Giordano (both KPMG) discussing the rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	0.4	\$ 65	50 \$	260.00
Thomas Giordano	01/20/20	Conference call with P. DiMatteo and T. Giordano (both KPMG) discussing the rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	0.4	\$ 35	50 \$	140.00

KPMG LLP Monthly Fee Statement

Page 45 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth14/8Fee68Application Pg 49 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Dawn Krishnamurthy	01/20/20	Discussion with M. Land and D. Krishnamurthy (KPMG) to discuss status of ongoing tax reserves and audits as related to project Malta (sell side diligence report).	0.4	\$	695	\$ 278.00
Michael Land	01/20/20	Discussion with M. Land and D. Krishnamurthy (KPMG) to discuss status of ongoing tax reserves and audits as related to project Malta (sell side diligence report).	0.4	\$	534	\$ 213.60
Thomas Heubach	01/20/20	Communication via email with D. Krishnamurthy (KPMG US) and P. Reer (KPMG Partner German Int'l Tax) regarding various items related to Purdue Pharma including process to update information request and best approach/next steps related to tax consulting services to be provided.	0.5	\$	750	\$ 375.00
Howard Steinberg	01/20/20	Call with H. Steinberg (KPMG), M. Hoffenberg (KPMG) and counsel at Akin regarding Norton Rose due diligence process	0.8	\$	856	\$ 684.80
Mark Hoffenberg	01/20/20	Call with H. Steinberg (KPMG), M. Hoffenberg (KPMG) and counsel at Akin regarding Norton Rose due diligence process	0.8	\$	980	\$ 784.00
Thomas Heubach	01/20/20	Review and concurrently compare received Purdue information with IRL (0.5); follow up via email on missing information with D. Krishnamurthy (KPMG US) and P. Reer (KPMG Partner German Intl Tax) (0.3).	0.8	\$	750	\$ 600.00
Christian Schmid	01/20/20	Partner review of Purdue Pharma information compiled to date from T. Heubach and S. Stricker (both KPMG Germany)	1.0	\$	985	\$ 985.00
Karen Erickson	01/20/20	Prepared entity schedule (provided by P. DiMatteo and T. Giordano - both KPMG), addressing discrepancies, for import into Legal Entity Manager in support of charting (0.8) and exchange emails with P. DiMatteo and T. Giordano (both KPMG) re specific items in schedule, such as preferred equity and country confirmation as well as chart presentation preferences (0.4)	1.2	\$	690	\$ 828.00
Isaac Hirsch	01/20/20	Perform Managing Director review of updates to bankruptcy tax consulting workplan (0.8) and Purdue Pharma organizational charts as of 1/20/2020 (0.7)	1.5	\$	819	\$ 1,228.50
Ashley Armfield	01/20/20	Senior Associate review of latest information request list to be sent to the client as of 1/20/2020.	1.5	\$	534	\$ 801.00
Dawn Krishnamurthy	01/20/20	1.9 Review of Purdue organizational charts for high priority jurisdictions for purpose of finalizing initial requests. 0.2 Preparing email listing litigation and audits (by jurisdiction) for purposes of gaining insight regarding tax exposures.	2.1	\$	695	\$ 1,459.50
Pete DiMatteo	01/20/20	Performed analysis regarding the application of the foreign tax credit rules to trusts and individuals to aid in planning and tax cost modeling	2.1	\$	650	\$ 1,365.00

191293838041941shl D 000089350-EiledFi0280033206/210nteEntel028003320612502690274:2181ainEtatribitment Copy of KPMG First MoPhth 14/9Fee68Application Pg 50 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Casey Nunez	01/20/20	Performed Senior manager review of data room findings for purposes of updating Purdue Pharma information request list.	2.1	\$	744	\$ 1,562.40
Dawn Krishnamurthy	01/20/20	Performed review of data room documentation as of 1/20 with focus on global structure.	2.3	\$	695	\$ 1,598.50
Jess Commisso	01/20/20	Performed analysis to determine whether assigned portion of Purdue financial statements are audited versus unaudited for member firm Mundipharma entities - pursuant to correspondence with member firms to request their review of such documentation.	2.6	\$	350	\$ 910.00
Michael Land	01/20/20	0.7 Review of correspondence with KPMG Germany regarding tax reserve / audits to gain insight regarding German tax profile; 0.7 review of correspondence with KPMG Korea regarding tax reserve / audits to gain insight regarding Korean tax profile; 0.7 review of correspondence with KPMG UK regarding tax reserve / audits to gain insight regarding UK tax profile; 0.6 review of correspondence with KPMG China re tax reserve / audits to gain insight regarding Chinese tax profile	2.7	\$	534	\$ 1,441.80
Dawn Krishnamurthy	01/20/20	0.7 Review of tax exam history described in meeting notes, E&Y Flowchart, Litigation Summaries and Project Malta due diligence report for purpose of identifying material tax exams (performed concurrently); 1.3 Manager review of financial statements provided in data room with focus on materiality; 0.8 Manager review of information request list as well as information received to date with respect to Swiss / South Korean updates.	2.8	\$	695	\$ 1,946.00
Maggie Scully	01/20/20	Comparing the information request list to the virtual data room to ensure KPMG US team has accurately accounted for all provided by client information received to date.	3.1	\$	350	\$ 1,085.00
Devon Rowles	01/20/20	Analysis to determine whether designated portion of Purdue financial statements are audited versus unaudited for my designated portion of member firm Mundipharma entities - pursuant to correspondence with member firms to request their review of such documentation.	3.4	\$	350	\$ 1,190.00
Thomas Giordano	01/20/20	Continued (same day) to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments	3.6	\$	350	\$ 1,260.00
Jess Commisso	01/20/20	Compiling the organizational charts of all Mundipharma entities provided by the client into a single file pursuant to mapping out relationships between jurisdictions and the global organizational chart.	3.9	\$	350	\$ 1,365.00

KPMG LLP Monthly Fee Statement Page 47 of 82

1912323049494shl D@0089350-EiledFi02d0332106/210nteEntel02d03321061250269024:2181ainEtatibitment Copy of KPMG First MoPth ByOFefe8Application Pg 51 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Thomas Giordano	01/20/20	Continued (from 1/17/2020) to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments	3.9	\$	350	\$ 1,365.00
Aroen Rambhadjan	01/21/20	Partner review of draft e-mail prepared by L. van der Veen (KPMG Netherlands) commenting on tax attributes available at the level of Dutch Purdue companies and recommendation related to a review of the (potential) impact of Dutch anti-hybrid rules on Dutch Purdue companies - prior to sending to D. Rowles (KPMG US)	0.5	\$	985	\$ 492.50
Dong-Ju Shin	01/21/20	Reviewed the Korean accounting standards for recognizing tax reserve and disclosing tax audits - with respect to request from D. Rowles (KPMG US) to review tax reserve, tax loss carryforwards, and tax audits in the audit reports of Mundipharma Korea Ltd.	0.5	\$	750	\$ 375.00
Ashley Armfield	01/21/20	Call with I. Hirsch (KPMG) and A. Armfield (KPMG) to discuss next round of updates that need to be made to cash tax model as of 1/21/2020.	0.9	\$	534	\$ 480.60
Isaac Hirsch	01/21/20	Call with I. Hirsch (KPMG) and A. Armfield (KPMG) to discuss next round of updates that need to be made to cash tax model as of 1/21/2020.	0.9	\$	819	\$ 737.10
Lukas van der Veen	01/21/20	Draft e-mail sent to D. Rowles (KPMG US) detailing comments related to tax attributes available at the level of Dutch Purdue companies including recommending a review of the (potential) impact of Dutch anti-hybrid rules on Dutch Purdue companies.	0.9	\$	730	\$ 657.00
Anja Poesl	01/21/20	Reviewed collection of tax information available for German entities (tax reserves, open tax audits or controversies and tax attribute carryforwards) with regards to German tax analysis to be performed.	0.9	\$	750	\$ 675.00
Kyung-Min Kim	01/21/20	(0.8) Per request from D. Rowles (KPMG US), reviewed 2016-2018 audit reports for Mundipharma Korea Ltd with focus on the existence of tax reserve, tax loss carryforwards, and tax audits; (0.2) responded to KPMG US email regarding same.	1.0	\$	750	\$ 750.00
Dawn Krishnamurthy	01/21/20	Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.	1.1	\$	695	\$ 764.50
Douglas Holland	01/21/20	Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.	1.1	\$	985	\$ 1,083.50

KPMG LLP Monthly Fee Statement Page 48 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth Byl Feetes Application Pg 52 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Isaac Hirsch	01/21/20	Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.	1.1	\$	819	\$ 900.90
Pete DiMatteo	01/21/20	Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.	1.1	\$	650	\$ 715.00
Jess Commisso	01/21/20	Continued (from same day) to research types of trusts, taxation of trusts, and details on Jersey trusts concurrently noting outcome of research to provide to team members, pursuant to trust analysis.	1.2	\$	350	\$ 420.00
Ashley Armfield	01/21/20	Reviewing comments provided by I. Hirsch (KPMG) to be discussed during upcoming call (same day) pursuant to cash tax modeling.	1.4	\$	534	\$ 747.60
Howard Steinberg	01/21/20	Performed Partner level review of high priority tax issue summary for purposes of gaining insight on tax posture	1.5	\$	856	\$ 1,284.00
Thomas Giordano	01/21/20	0.6 Drafted an outline deductibility research findings to circulate to team; 0.2 drafted email to outline on deductibility research to P. DiMatteo (KPMG); 0.7 Reviewed excel formatted organization structure to verify accurate country codes to be used in overall global organization structure.	1.5	\$	350	\$ 525.00
Philipp Reer	01/21/20	German Tax Partner review of summary of tax positions in financial statements prepared by T. Heubach (KPMG).	1.6	\$	765	\$ 1,224.00
Karen Erickson	01/21/20	For purposes of having a dynamic presentation of the legal entity structure: Set up project in Legal Entity Manager (LEM) (0.1) and create relevant entity attributes (0.4). Transfer entity information presentation to necessary import templates (1.0) and follow up with P. DiMatteo and T. Giordano (both KPMG) on information (0.3).	1.8	\$	690	\$ 1,242.00
Dawn Krishnamurthy	01/21/20	1.8 Performed analysis regarding Pharmaceutical Research Associates Taiwan, Inc. for purpose of gaining insight regarding ownership; 0.2 Manager review of summary of high priority tax issues for purposes of gain insight regarding rationale for information requests.	2.0	\$	695	\$ 1,390.00
Pete DiMatteo	01/21/20	Additional analysis regarding deductibility of settlement payments, including cases where restitution deductions were deemed permissible.	2.1	\$	650	\$ 1,365.00

KPMG LLP Monthly Fee Statement Page 49 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	ŀ	Rate	Amount
Jess Commisso	01/21/20	Continued (from 1/20) to compile the organizational charts of all Mundipharma entities provided by the client into a single file pursuant to mapping out relationships between jurisdictions and the global organizational chart	2.2	\$	350	\$ 770.00
Isaac Hirsch	01/21/20	Performed analysis of Purdue cash tax model to build out for foreign tax credit categories.	2.9	\$	819	\$ 2,375.10
Thomas Giordano	01/21/20	Continue, from 1/20/2020, to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	3.0	\$	350	\$ 1,050.00
Pete DiMatteo	01/21/20	Perform analysis on the permissibly of deductions for settlement payments, including whether an individual is deemed to operate a business under section 162	3.2	\$	650	\$ 2,080.00
Lukas van der Veen	01/21/20	Upon request of D. Rowles (KPMG US), review information included in share file on Dutch Purdue companies for 2016 - 2018 including financial statements / local Dutch transfer pricing documentation in order to identify tax attributes available at the level of the Dutch Purdue companies.	3.2	\$	730	\$ 2,336.00
Thomas Heubach	01/21/20	Senior Manager review and concurrently reconcile information prepared by S. Stricker (KPMG Germany) as requested by D. Rowles (KPMG US) regarding tax reserves, open tax audits and tax attributes carryforwards for all Purdue entities (total of 9).	3.5	\$	750	\$ 2,625.00
Devon Rowles	01/21/20	(2.3) Creating an excel tracker to keep inventory of all the information received from KPMG member firms to date (1.3) Review of virtual data room for additional documents uploaded as of 1/21/20.	3.6	\$	350	\$ 1,260.00
Ashley Armfield	01/21/20	Updated the Purdue cash tax model relating to the disposition scenarios i.e., stock versus asset functionality.	3.6	\$	534	\$ 1,922.40
Sonia Stricker	01/21/20	Compiled and concurrently reviewed information requested by D. Rowles (KPMG US) regarding tax reserves, open tax audits and tax attributes carryforwards for all Purdue entities (total of 9).	3.8	\$	380	\$ 1,444.00
Jess Commisso	01/21/20	Researched types of trusts, taxation of trusts, as well as details on Jersey trusts, while simultaneously noting outcome of research to provide to rest of the team, pursuant to trust analysis.	3.9	\$	350	\$ 1,365.00
Sam Tyler	01/21/20	Call with G. Bell and J. Lau (both KPMG Canada) to discuss overview of Purdue Canadian structure to understand potential tax implications of a disposition	0.5	\$	743	\$ 371.50
Jonas Lau	01/21/20	Call with G. Bell and J. Lau (both KPMG Canada) to discuss overview of Purdue Canadian structure to understand potential tax implications of a disposition	0.5	\$	614	\$ 307.00

KPMG LLP Monthly Fee Statement

Page 50 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By Stefes Application Pg 54 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	;	Amount
Gregory Bell	01/21/20	Call with G. Bell and J. Lau (both KPMG Canada) to discuss overview of Purdue Canadian structure to understand potential tax implications of a disposition	0.5	\$ 74	3 \$	371.50
Jonas Lau	01/21/20	Began to perform initial Senior Manager review of Purdue Canadian organizational charts/entities in conjunction with available financial statements to gain insight regarding client structure.	0.5	\$ 61	4 \$	307.00
Jonas Lau	01/22/20	Continued, from 1/21, to perform a Senior Manager level review of Purdue Canadian organizational charts/entities in conjunction with available financial statements to gain insight regarding client structure.	2.0	\$ 61	4 \$	1,228.00
Gregory Bell	01/21/20	Performed initial Partner review provided by client documentation in the data room from a Canadian tax perspective.	0.5	\$ 74	.3 \$	371.50
Oron Zeevi	01/22/20	Discussion with A. Eytan (KPMG) regarding the Purdue Pharma Israeli entity financial statements, current data available related to tax reserves and other tax attributes, as well as what additional information should be requested from KPMG US.	0.5	\$ 45	0 \$	225.00
Arik Eytan	01/22/20	Discussion with A. Eytan (KPMG) regarding the Purdue Pharma Israeli entity financial statements, current data available related to tax reserves and other tax attributes, as well as what additional information should be requested from KPMG US.	0.5	\$ 55	5 \$	277.50
Gavin Little	01/22/20	Performed Senior manager review of the analysis prepared by A. Desai and M. Latham (both KPMG UK) of the Purdue UK companies prior to submission to the KPMG US team.	0.5	\$ 98	5 \$	492.50
Gavin Little	01/22/20	Review of the term sheet provided by KPMG US while concurrently drafting comments regarding UK tax analysis along with the review comments provided by A. Desai (KPMG UK Senior Manager) related to same.	0.5	\$ 98	5 \$	492.50
Arpit Desai	01/22/20	Reviewed term sheet provided by KPMG US and concurrently draft comments regarding UK tax analysis to provide to G. Little (KPMG UK Director).	0.5	\$ 75	0 \$	375.00
Isaac Hirsch	01/22/20	Conference with I. Hirsch and P. DiMatteo (both KPMG) to discuss / refine research regarding deductions arising from settlement payments to aid in tax planning and modeling	0.8	\$ 81	9 \$	655.20
Pete DiMatteo	01/22/20	Conference with I. Hirsch and P. DiMatteo (both KPMG) to discuss / refine research regarding deductions arising from settlement payments to aid in tax planning and modeling	0.8	\$ 65	0 \$	520.00

KPMG LLP Monthly Fee Statement Page 51 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By4Fee68Application Pg 55 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Ra	te	Amount
Karen Erickson	01/22/20	Provide import templates as well as sample organizational charts for consideration to P. DiMatteo and T. Giordano (0.2); Initiated alternate sorting of entities to mitigate separation of parent and sub in chart where possible (0.6)	0.8	\$	690	\$ 552.00
Dawn Krishnamurthy	01/22/20	0.8 Review of most recent data uploaded to Norton Rose data room as of 1/22/2020 to identify tax relevant items; 0.2 Performed Manager review of draft email prepared by A. Armfield (KPMG) to be sent to KPMG Swiss member firm for purpose of engaging Swiss team to perform services for Purdue.	1.0	\$	695	\$ 695.00
Oron Zeevi	01/22/20	Drafted email to J. Commisso (KPMG US) detailing initial findings following the review of the financial statements with respect to tax reserves, tax attributes, etc.	1.0	\$ 4	450	\$ 450.00
Arik Eytan	01/22/20	Partner level review of the 2016 - 2018 financial statements of the Purdue Pharma Israeli entity in order to assess available tax reserves, tax attributes, operations and financial results.	1.0	\$:	555	\$ 555.00
Pete DiMatteo	01/22/20	Continue (same day) to perform analysis related to the deductibility of settlement payments - relating to contemplated payments made by trusts/individual beneficiaries to the settlement vehicle under section 162.	1.5	\$	650	\$ 975.00
Thomas Heubach	01/22/20	Review of audited financial statements (including related findings) of S. Stricker (KPMG Germany) related to quantified tax audit adjustments requested by D. Krishnamurthy (KPMG US) for Purdue entities Mundipharma Deutschland GmbH & Co. KG and Mundipharma GmbH	1.7	\$	750	\$ 1,275.00
Pete DiMatteo	01/22/20	Review of legal entity manager output for purposes of creating a global organization chart	1.8	\$	650	\$ 1,170.00
Madeleine Latham	01/22/20	Meeting with A. Desai (KPMG UK) to analyze and concurrently discuss the accounts for the Purdue UK companies in scope in order to identify tax reserves, open tax audits or controversies, and tax attributes, as requested by KPMG US in an email dated 01/21/20. Note: two individuals performed this task given the volume of material to analyze (for 15 companies across three financial years) and the deadline set by KPMG US.	2.0	\$	380	\$ 760.00

KPMG LLP Monthly Fee Statement Page 52 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth BySFee68Application Pg 56 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Arpit Desai	01/22/20	Meeting with M. Latham (KPMG UK) to analyze and concurrently discuss the accounts for the Purdue UK companies in scope in order to identify tax reserves, open tax audits or controversies, and tax attributes, as requested by KPMG US in an email dated 01/21/20. Note: two individuals performed this task given the volume of material to analyze (for 15 companies across three financial years) and the deadline set by KPMG US.	2.0	\$	750	\$ 1,500.00
Ashley Armfield	01/22/20	0.8 Performed Senior Associate review of preliminary structuring deck for Mundipharma MEA GmbH tax consequences pursuant to preparing a structure deck of tax consequences. 1.4 Created cash tax model inputs summary tab to allow functionality between scenario inputs.	2.2	\$	534	\$ 1,174.80
Ashley Armfield	01/22/20	Perform updates to cash tax model to include functionality of different foreign tax credit baskets (i.e., GILTI, passive), income classification baskets (i.e., GILTI, US-Source), and character (i.e., ordinary versus capital) - this was all one task as all items are related.	2.2	\$	534	\$ 1,174.80
Sonia Stricker	01/22/20	Analyze / investigate audited financial statements for quantified tax audit adjustments requested by D. Krishnamurthy (KPMG US) for Purdue entities Mundipharma Deutschland GmbH & Co. KG and Mundipharma GmbH	2.5	\$	380	\$ 950.00
Oron Zeevi	01/22/20	Senior Manager level review of the 2016 - 2018 financial statements of the Purdue Pharma Israeli entity in order to assess available tax reserves, tax attributes, operations and financial results.	2.5	\$	450	\$ 1,125.00
Thomas Giordano	01/22/20	Continued, from earlier in the day, to cross-check LEM created global organization structure chart (of approximately 325 entities) with excel formatted organization structure to determine accuracy of overall global organization structure.	2.6	\$	350	\$ 910.00
Jess Commisso	01/22/20	Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	2.7	\$	350	\$ 945.00
Ashley Armfield	01/22/20	Updates to cash tax model based on managing director comments to combine US tax and foreign tax credit calculations into one tab.	2.9	\$	534	\$ 1,548.60
Devon Rowles	01/22/20	Began to create an outline to cover tax research around the deductibility of restitution payments.	3.2	\$	350	\$ 1,120.00

KPMG LLP Monthly Fee Statement Page 53 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By6Fee68Application Pg 57 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	Rate	Amount
Dawn Krishnamurthy	01/22/20	1.1 Review of Norton Rose data room financial statements in conjunction with Advance Pricing Agreement (APA) agreements for purpose of updating information request list; 1.6 Manager review of trust research performed by J. Commisso (KPMG); 0.8 Manager review of German audit exposure issue for purpose of drafting follow-up email to German team.	3.5	\$	695	\$ 2,432.50
Dawn Krishnamurthy	01/22/20	2.9 Perform analysis related to trust / disregarded entity tax treatment for purposes of understanding treatment of potential distribution of Mundipharma sales proceeds; 0.4 Performed analysis related to Section 481 adjustments with regards to Purdue Pharma tax matter; 0.4 performed additional analysis regarding ownership of Pharmaceutical Research Associates Taiwan Inc. for risk management purposes.	3.7	\$	695	\$ 2,571.50
Jess Commisso	01/22/20	Began to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. Note: this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/22/20	Began to cross-check LEM created global organization structure chart (related to numerous Purdue Pharma entities) with excel formatted organization structure to determine accuracy of overall global organization structure.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/22/20	Continue, same day, to cross-check LEM created global organization structure chart (related to numerous Purdue Pharma entities) with excel formatted organization structure to determine accuracy of overall global organization structure.	3.9	\$	350	\$ 1,365.00
Pete DiMatteo	01/22/20	Performed analysis related to the deductibility of settlement payments - relating to contemplated payments made by trusts/individual beneficiaries to the settlement vehicle under section 162.	3.9	\$	650	\$ 2,535.00
Jonas Lau	01/22/20	Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.	0.5	\$	614	\$ 307.00
Sam Tyler	01/22/20	Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.	0.5	\$	743	\$ 371.50

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By/Fee68Application Pg 58 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Gregory Bell	01/22/20	Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.	0.5	\$	743	\$ 371.50
Sam Tyler	01/22/20	Partner review of all available documentation in data room to consider Canadian tax issues (0.4) and drafted respond to request from KPMG US (0.4)	0.8	\$	743	\$ 594.40
Christin Witt	01/23/20	Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.	0.4	\$	650	\$ 260.00
Philipp Reer	01/23/20	Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.	0.4	\$	765	\$ 306.00
Anja Poesl	01/23/20	Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.	0.4	\$	750	\$ 300.00
Thomas Giordano	01/23/20	Continue, on same day, to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure	0.5	\$	350	\$ 175.00
Jess Commisso	01/23/20	Continued (from 1/21) to research types of trusts, taxation of trusts, as well as details on Jersey trusts, while simultaneously creating notes for distribution to the rest of the team, pursuant to trust analysis.	0.8	\$	350	\$ 280.00
Isaac Hirsch	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$	819	\$ 737.10
Karen Erickson	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$	690	\$ 621.00
Pete DiMatteo	01/23/20		0.9	\$	650	\$ 585.00
Thomas Giordano	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$	350	\$ 315.00

KPMG LLP Monthly Fee Statement Page 55 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By Fefes Application Pg 59 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Dawn Krishnamurthy	01/23/20	Performed analysis regarding ownership structure of Mundipharma entities with focus on tax issues related to distribution of sales proceeds.	1.2	\$	695	\$ 834.00
Ashley Armfield	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$	534	\$ 694.20
Casey Nunez	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$	744	\$ 967.20
Dawn Krishnamurthy	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$	695	\$ 903.50
Isaac Hirsch	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$	819	\$ 1,064.70
Jess Commisso	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$	350	\$ 455.00
Jess Commisso	01/23/20	Incorporated UK financial statement analysis of tax attributes, reserves and audits into a combined file of all member firm entities pursuant to Mundipharma entity analysis.	1.3	\$	350	\$ 455.00
Isaac Hirsch	01/23/20	Managing Director review of latest set of updates to organizational charts sent by P. DiMatteo (KPMG)	1.5	\$	819	\$ 1,228.50
Ashley Armfield	01/23/20	Updated cash tax model structure / data (about the Mundipharma entities as provided in the Norton Rose calculations) for Mundipharma Deutschland GmbH & Co KG to conform with all prior updates.	2.1	\$	534	\$ 1,121.40
Ashley Armfield	01/23/20	Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint.	2.2	\$	534	\$ 1,174.80

KPMG LLP Monthly Fee Statement Page 56 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	01/23/20	Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint.	2.2	\$ 350	\$ 770.00
Jess Commisso	01/23/20	Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint.	2.2	\$ 350	\$ 770.00
Jess Commisso	01/23/20	Continue (from 1/22) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	2.4	\$ 350	\$ 840.00
Isaac Hirsch	01/23/20	Review modifications to cash tax model incorporating latest round of comments from the project team sent by A. Armfield (KPMG)	3.1	\$ 819	\$ 2,538.90
Devon Rowles	01/23/20	1.1 Created a summary / index of all of the VDR documents received to date in preparation to provide to KPMG US and member firm project teams; 2.1 Continue (from 1/22) to create an outline to cover tax research around the deductibility of restitution payments	3.2	\$ 350	\$ 1,120.00
Pete DiMatteo	01/23/20	Continue (same day) drafting organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).	3.2	\$ 650	\$ 2,080.00
Pete DiMatteo	01/23/20	Draft organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).	3.4	\$ 650	\$ 2,210.00
Ashley Armfield	01/23/20	Updating cash tax model to add interim step and concurrently compile all data (i.e., cash flows to local country authorities, different types of taxable income) from entity level tabs into one main tab.	3.5	\$ 534	\$ 1,869.00
Thomas Giordano	01/23/20	Continue (from 1/22) to cross-check LEM created global organization structure chart related to numerous Purdue Pharma entities with excel formatted organization structure to determine accuracy of overall global organization structure	3.6	\$ 350	\$ 1,260.00

KPMG LLP Monthly Fee Statement Page 57 of 82

1912323649494shl Doboo 89350-Eiled Filed 02332106/210 nt de Ente 02d 0233210612502690274:2181 ain Extribit munt Copy of KPMG First Month by OF de Bapplication Pg 61 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Thomas Giordano	01/23/20	Began to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure	3.9	\$	350	\$ 1,365.00
Dawn Krishnamurthy	01/23/20	0.2 Drafting email to C. Nunez (KPMG) regarding ownership of Pharmaceutical Research Associates Taiwan, Inc.; 2.3 Comparison of Norton Rose Calculations to KPMG draft model; 0.6 Manager review of Swiss PowerPoint asset/stock sale analysis structure - prepared by J. Commisso (KPMG); 0.9 Review of Purdue court filings to identify entity ownership information.	4.0	\$	695	\$ 2,780.00
Andy Farinich	01/23/20	Created 5 slides depicting various distribution scenarios which showed the potential tax consequences if payments were to be made from the beneficiary level, or from the trust level, into the settlement vehicle.	1.5	\$	534	\$ 801.00
Andy Farinich	01/23/20	Began to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)	3.5	\$	534	\$ 1,869.00
Sam Tyler	01/23/20	Review draft email from J. Lau (KPMG Canada) summarizing Canadian tax review of available document and concurrently draft review comments	0.3	\$	743	\$ 222.90
Danielle Moloughney	01/23/20	Performed Associate level review of Purdue Canadian financial statements and other available documentation for purposes of understanding Purdue Canada's financial position	1.6	\$	172	\$ 275.20
Jonas Lau	01/23/20	Continued to review organizational charts along with other available financial statements concurrently to identify potential tax exposures (1.5), email correspondence with KPMG US to describe findings related to same (0.5)	2.0	\$	614	\$ 1,228.00
Karen Erickson	01/24/20	Complete revisions of structure of entities for better positioning of owner and subsidiaries in the Purdue Pharma organizational chart (0.4). Import schedules to LEM - based on data and notes updates as of 1/24/2020 (0.1).	0.5	\$	690	\$ 345.00
Casey Nunez	01/24/20	Performed a senior manager review of data room updates as of 1/24 to identify new Purdue Pharma documents.	1.2	\$	744	\$ 892.80
Howard Steinberg	01/24/20	Partner review of data room updates as of 1/24/2020 to identify new tax relevant documents	1.3	\$	856	\$ 1,112.80
Ashley Armfield	01/24/20	Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.	1.6	\$	534	\$ 854.40

KPMG LLP Monthly Fee Statement Page 58 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth Byl Feetes Application Pg 62 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Devon Rowles	01/24/20	Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.	1.6	\$	350	\$ 560.00
Jess Commisso	01/24/20	Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.	1.6	\$	350	\$ 560.00
Ashley Armfield	01/24/20	Drafting template and corresponding email discussing structure deck outline for potential dispositions to be send to KPMG project team (i.e., P. DiMatteo, I. Hirsch, C. Nunez).	1.6	\$	534	\$ 854.40
Devon Rowles	01/24/20	Finalized outline to cover tax research around the deductibility of restitution payments - continued from 1/23.	1.8	\$	350	\$ 630.00
Ashley Armfield	01/24/20	Discussion with D. Rowles and A. Armfield (both KPMG) regarding the cash flow steps involved with the sale of Purdue Pharma (Canada) pursuant to providing a structure chart in PowerPoint.	2.1	\$	534	\$ 1,121.40
Devon Rowles	01/24/20	Discussion with D. Rowles and A. Armfield (both KPMG) regarding the cash flow steps involved with the sale of Purdue Pharma (Canada) pursuant to providing a structure chart in PowerPoint.	2.1	\$	350	\$ 735.00
Jess Commisso	01/24/20	Continued, from previous day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes	2.5	\$	350	\$ 875.00
Thomas Giordano	01/24/20	Continued (from 1/23) to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.	2.7	\$	350	\$ 945.00
Dawn Krishnamurthy	01/24/20	1.3 Review of Project Malta financial due diligence reports with focus on vendor due diligence findings; 0.1 Review new document "FW IAC Follow Up Requests.msg" in Norton Rose Data Room; 1.1 Review of terms of Purdue transfer of assets to Newco in term sheet; 0.3 Manager review of schedule of assets and liabilities of Purdue Pharma LP for tax liens/liabilities.	2.8	\$	695	\$ 1,946.00
Dawn Krishnamurthy	01/24/20	2.6 Drafted summary of tax relevant information contained in Project Malta Report Volume 1 (report was over 400 pages); 0.2 Manager review of Project Malta summary prepared by M. Land (KPMG).	2.8	\$	695	\$ 1,946.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPtth By2Fee68Application Pg 63 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	ŀ	Rate	Amount
Dawn Krishnamurthy	01/24/20	1.2 Review of Debtors Informational Brief filed by Purdue with focus on whether the organizational structure had been disclosed as well as what payments were going to be required (and from which entities) in order to gain insight regarding where the cash needs to move within the structure to identify potential tax issues); 2.0 Perform research regarding proposed settlement as described in bankruptcy court filings	3.2	\$	695	\$ 2,224.00
Isaac Hirsch	01/24/20	(1.4) Continued (from 1/23) Managing Director review of updates to organizational charts sent by P. DiMatteo (KPMG) (2.3) Drafted comments related to cash tax model to account for rate disparity rules	3.7	\$	819	\$ 3,030.30
Pete DiMatteo	01/24/20	Continued (from 1/23) to draft and concurrently analyze organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).	3.8	\$	650	\$ 2,470.00
Jess Commisso	01/24/20	Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes - as began earlier in the day.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/24/20	Continued (from earlier in the day) to create assigned portion of global organizational structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/24/20		3.9	\$	350	\$ 1,365.00
Andy Farinich	01/24/20	Continued, from earlier in the day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)	1.5	\$	534	\$ 801.00
Andy Farinich	01/24/20	Continue, from previous day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)	3.9	\$	534	\$ 2,082.60
Andy Farinich	01/24/20		3.9	\$	534	\$ 2,082.60
Dawn Krishnamurthy	01/26/20	Review of Project Malta report Volume 1 for purpose of identifying potential tax exposures.	0.8	\$	695	\$ 556.00

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPtth By 3Feetes Application Pg 64 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Pete DiMatteo	01/26/20	Perform Manager review and concurrently revise Visio organization structures to confirm ownership for purposes of draft a slide deck depicting relevant contemplated transactions.	3.1	\$	650	\$ 2,015.00
Pete DiMatteo	01/27/20	Call with A. Farinich and P. DiMatteo (KPMG) to discuss next steps related to the drafting of slides depicting alternative transactions for 3 UK entities and German entities.	0.5	\$	650	\$ 325.00
Andy Farinich	01/27/20	Call with A. Farinich and P. DiMatteo (KPMG) to discuss next steps related to the drafting of slides depicting alternative transactions for 3 UK entities and German entities.	0.5	\$	534	\$ 267.00
Ashley Armfield	01/27/20	Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions	1.2	\$	534	\$ 640.80
Devon Rowles	01/27/20	Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions	1.2	\$	350	\$ 420.00
Isaac Hirsch	01/27/20	Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions	1.2	\$	819	\$ 982.80
Michael Land	01/27/20	Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions	1.2	\$	534	\$ 640.80
Michael Land	01/27/20	Meeting with M. Land and A. Armfield (all KPMG) to discuss structuring alternatives re Switzerland disposition	1.3	\$	534	\$ 694.20
Ashley Armfield	01/27/20	Meeting with M. Land and A. Armfield (all KPMG) to discuss structuring alternatives regarding Switzerland disposition	1.3	\$	534	\$ 694.20
Ashley Armfield	01/27/20	Meeting with A. Armfield and M. Land (all KPMG) discuss structuring alternatives re Canada disposition	1.4	\$	534	\$ 747.60
Michael Land	01/27/20	Meeting with A. Armfield and M. Land (all KPMG) discuss structuring alternatives re Canada disposition	1.4	\$	534	\$ 747.60
Devon Rowles	01/27/20	Creating a structure deck for Purdue Pharma (Canada) related to individual country dispositions and foreign tax consequences	1.9	\$	350	\$ 665.00
Ashley Armfield	01/27/20	Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences	1.9	\$	534	\$ 1,014.60
Dawn Krishnamurthy	01/27/20	Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences	1.9	\$	695	\$ 1,320.50

KPMG LLP Monthly Fee Statement Page 61 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPtth By4Fee68Application Pg 65 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Devon Rowles	01/27/20	Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences	1.9	\$	350	\$ 665.00
Isaac Hirsch	01/27/20	Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences	1.9	\$	819	\$ 1,556.10
Michael Land	01/27/20	Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences	1.9	\$	534	\$ 1,014.60
Isaac Hirsch	01/27/20	(1.4) Update comments to cash tax model to incorporate foreign tax credit baskets in preparation for meeting with team regarding same; (0.8) review of Purdue updated organizational charts for purposes of preparing cash tax cost analysis	2.2	\$	819	\$ 1,801.80
Jess Commisso	01/27/20	0.4 Correspondence with KPMG Canada regarding information requests pursuant to tax analysis; 1.9 Incorporated Canada financial statement analysis of tax attributes, reserves and audits into a combined file of all Member Firm (MF) entities pursuant to Mundipharma entity analysis	2.3	\$	350	\$ 805.00
Pete DiMatteo	01/27/20	Perform detailed manager review of 8 organizational structures to be used in a PowerPoint presentation depicting contemplated transactions for purposes of assisting in tax cost modeling.	3.2	\$	650	\$ 2,080.00
Dawn Krishnamurthy	01/27/20	Performed Manager review of latest version of Purdue draft cash tax model as of 1/27.	3.3	\$	695	\$ 2,293.50
Ashley Armfield	01/27/20	Creating Mundipharma MEA GmbH structure and initial steps in PowerPoint pursuant to preparing structuring deck to share with member firms.	3.5	\$	534	\$ 1,869.00
Andy Farinich	01/27/20	Began creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.	3.9	\$	534	\$ 2,082.60
Andy Farinich	01/27/20	Continued (in same day) creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.	3.9	\$	534	\$ 2,082.60

KPMG LLP Monthly Fee Statement Page 62 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPtth By-SFeetes Application Pg 66 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Thomas Giordano	01/27/20	Began to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; Note: These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was sometimes partially unreadable.	4.0	\$	350	\$ 1,400.00
Thomas Giordano	01/27/20	Continued (from earlier in the day) to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; Note: These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was sometimes partially unreadable.	4.0	\$	350	\$ 1,400.00
Dawn Krishnamurthy	01/28/20		0.9	\$	695	\$ 625.50
Andy Farinich	01/28/20	focus on tax profile of Mundipharma entities. Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.	0.9	\$	534	\$ 480.60
Ashley Armfield	01/28/20	Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.	0.9	\$	534	\$ 480.60
Michael Land	01/28/20	Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.	0.9	\$	534	\$ 480.60
Thomas Giordano	01/28/20	Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.	0.9	\$	350	\$ 315.00
Jess Commisso	01/28/20	0.6 Correspondence with UK Member Firm to discuss tax implications of deemed distributions of trusts and what is needed from the client in regards to trust information. 0.8 Researched types of trusts, taxation of trusts as well as details on Jersey trusts while simultaneously preparing notes to disseminate to project team, pursuant to trust analysis.	1.4	\$	350	\$ 490.00
Ashley Armfield	01/28/20	Updating assumptions for structure deck based on review comments received from I. Hirsch (KPMG) as of 1/28/2020.	1.6	\$	534	\$ 854.40
Ashley Armfield	01/28/20	Created structure deck support file in excel to outline calculations used for the Purdue Pharma structure deck.	1.9	\$	534	\$ 1,014.60

KPMG LLP Monthly Fee Statement Page 63 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth By6Fee68Application Pg 67 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	Rate	Amount
Jess Commisso	01/28/20	Continued (from same day), to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes	2.7	\$	350	\$ 945.00
Michael Land	01/28/20	Continued, from earlier in the day, to prepare initial draft of Mundipharma DC B.V.'s asset disposition scenario	2.7	\$	534	\$ 1,441.80
Michael Land	01/28/20	Review of Mundipharma DC B.V. structure in conjunction with the Purdue cash flow model for purposes of structuring	2.9	\$	534	\$ 1,548.60
Devon Rowles	01/28/20	Continue, from earlier in the day, to create a structure deck for Purdue Pharma (Canada) related to individual country dispositions and foreign tax consequences.	3.1	\$	350	\$ 1,085.00
Dawn Krishnamurthy	01/28/20	Manager review of notes prepared by M. Land (KPMG) from Project Malta reports Volumes 1- 2 for the purpose of gaining insight regarding tax profile of the Mundipharma entities.	3.4	\$	695	\$ 2,363.00
Dawn Krishnamurthy	01/28/20	0.8 Review of financial statements of Purdue Indian entities to identify relevant tax information; 2.7 Review of Project Malta report Volume I with focus on tax profile of Mundipharma entities.	3.5	\$	695	\$ 2,432.50
Thomas Giordano	01/28/20	Continued, from earlier in the day, to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; Note: These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was Sometimes partially unreadable.	3.6	\$	350	\$ 1,260.00
Ashley Armfield	01/28/20	Senior associate review of structure deck for CH13 - Mundipharma MEA GmbH asset sale scenario.	3.6	\$	534	\$ 1,922.40
Frank Caratzola	01/28/20	2.7 Performed research related to the applicability of Section 162 deduction for ordinary and necessary expenses paid or incurred in carrying on a "trade or business" to client facts; 1.0 Performed research related to the applicability of Section 165 and Section 212 deductions to client facts	3.7	\$	534	\$ 1,975.80
Devon Rowles	01/28/20	Creating a simplified excel model for Purdue Pharma (Canada) to correlate with Purdue Pharma (Canada) structure deck with regards to individual country dispositions and tax consequences.	3.7	\$	350	\$ 1,295.00
Michael Land	01/28/20	Begin to prepare initial draft of Mundipharma DC B.V.'s asset disposition scenario	3.9	\$	534	\$ 2,082.60

KPMG LLP Monthly Fee Statement Page 64 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPtth 16y7Fee68Application Pg 68 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Andy Farinich	01/28/20	Continue (from previous day) creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.	3.9	\$	534	\$ 2,082.60
Andy Farinich	01/28/20	Continue (same day) creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.	3.9	\$	534	\$ 2,082.60
Jess Commisso	01/28/20	Continued (from 1/24), to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. Note: this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck.	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/28/20	Continued (from1/27) to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; Note: These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was Sometimes partially unreadable.	3.9	\$	350	\$ 1,365.00
Howard Steinberg	01/28/20	Partner review of updated workplan for purposes of determining project strategy	1.7	\$	856	\$ 1,455.20
Ashley Armfield	01/29/20	Meeting with A. Armfield, J. Commisso, and D. Rowles (all KPMG) to discuss updates that need to be made to the proposed disposition structure deck (asset versus stock analysis) of entities as provided by Norton Rose.	0.4	\$	534	\$ 213.60
Devon Rowles	01/29/20	Meeting with A. Armfield, J. Commisso, and D. Rowles (all KPMG) to discuss updates that need to be made to the proposed disposition structure deck (asset versus stock analysis) of entities as provided by Norton Rose.	0.4	\$	350	\$ 140.00
Jess Commisso	01/29/20	Meeting with A. Armfield, J. Commisso, and D. Rowles (all KPMG) to discuss updates that need to be made to the proposed disposition structure deck (asset versus stock analysis) of entities as provided by Norton Rose.	0.4	\$	350	\$ 140.00

KPMG LLP Monthly Fee Statement Page 65 of 82

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Thomas Giordano	01/29/20	Continue (on same day) additional development structure deck disposition scenarios for Napp Pharmaceutical Holdings Limited.	1.1	\$	350	\$ 385.00
Thomas Giordano	01/29/20	Continued (same day) additional development of structure deck disposition scenarios regarding Mundipharma Medical Company Limited	1.1	\$	350	\$ 385.00
Ashley Armfield	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternative scenarios with regards to overall strategy	1.1	\$	534	\$ 587.40
Michael Land	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternative scenarios with regards to overall strategy	1.1	\$	534	\$ 587.40
Ashley Armfield	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma MEA GmbH.	1.2	\$	534	\$ 640.80
Michael Land	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma MEA GmbH.	1.2	\$	534	\$ 640.80
Isaac Hirsch	01/29/20	Communication via email with P. DiMatteo (KPMG) regarding research related to the deductibility of settlement payments	1.3	\$	819	\$ 1,064.70
Dawn Krishnamurthy	01/29/20	Review of Purdue Pharma transfer pricing documentation for purpose of identifying potential tax exposures.	1.5	\$	695	\$ 1,042.50
Pete DiMatteo	01/29/20	Update outline detailing section 162 research for purposes of determining whether a deduction is permissible for settlement payments	1.6	\$	650	\$ 1,040.00
Ashley Armfield	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma DC B.V.	2.3	\$	534	\$ 1,228.20
Michael Land	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma DC B.V.	2.3	\$	534	\$ 1,228.20
Devon Rowles	01/29/20	Update the Switzerland structure deck (per direction from A. Armfield and M. Land - both of KPMG) with specific regards to individual country dispositions / tax consequences	2.4	\$	350	\$ 840.00
Frank Caratzola	01/29/20	0.3 Compiled a listing of the trusts in Client's entity structure and concurrently identified the beneficiaries of each in an excel workbook; 2.3 Performed research regarding foreign tax credit ("FTC") rules under sections 901/904 as they related to the specific entity structures in Client's facts	2.6	\$	534	\$ 1,388.40
Isaac Hirsch	01/29/20	Performed Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments	2.8	\$	819	\$ 2,293.20

KPMG LLP Monthly Fee Statement Page 66 of 82

191293838041941shl D 000089350-Eiled Filed 0033206/210 nt 0 25 0 0 12 0 2 12 0 12 0 2 12 0 1

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Ashley Armfield	01/29/20	Preparing Mundipharma MEA GmbH tax steps associated with a stock disposition pursuant to preparing structuring deck to be sent to KPMG member firms to facilitate tax analyses.	2.9	\$	534	\$ 1,548.60
Dawn Krishnamurthy	01/29/20	0.3 Review of information request list for purpose of identifying most critical items; 2.7 Manager review of data room information related to entities located in high priority jurisdictions for purposes of disposition scenario structure deck.	3.0	\$	695	\$ 2,085.00
Pete DiMatteo	01/29/20	Continue (same day) to draft a PowerPoint presentation with focus on depicting contemplated transactions	3.2	\$	650	\$ 2,080.00
Devon Rowles	01/29/20	Updated the Netherlands structure deck (per direction from A. Armfield and M. Land - both of KPMG) with specific regards to individual country dispositions / tax consequences	3.3	\$	350	\$ 1,155.00
Pete DiMatteo	01/29/20	Drafted a PowerPoint presentation depicting contemplated asset/stock sales and subsequent distributions.	3.6	\$	650	\$ 2,340.00
Frank Caratzola	01/29/20	•	3.7	\$	534	\$ 1,975.80
Thomas Giordano	01/29/20	Additional development/updates to the structure deck disposition scenarios for Mundipharma Medical Company Limited with regard to clarification received, based on discussion with the project team, regarding best approach to interpret previously received PBC data that was partially unreadable (with respect to transaction steps).	3.9	\$	350	\$ 1,365.00
Thomas Giordano	01/29/20		3.9	\$	350	\$ 1,365.00
Jess Commisso	01/29/20	Continue, from earlier in the day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. Note: this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck.	3.9	\$	350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours]	Rate	Amount
Jess Commisso	01/29/20	Continued (from 1/24) to create illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	3.9	\$	350	\$ 1,365.00
Howard Steinberg	01/29/20	Perform Partner review of data room information for purposes of determining tax posture	1.0	\$	856	\$ 856.00
Thomas Giordano	01/30/20	Continued (same day) to draft detailed email to project team explaining an identified ownership depiction issue regarding four entities in the Mundipharma MEA GmbH organization structure that had effects across multiple entities' organization structures	0.3	\$	350	\$ 105.00
Thomas Giordano	01/30/20	Continued (same day) to further refine the structure deck disposition scenarios for Mundipharma Medical Company Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve) - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to be consistent.	0.5	\$	350	\$ 175.00
Thomas Giordano	01/30/20	Continue (on same day) to further refine the structure deck disposition scenarios for Mundibiopharma Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to consistent).	0.6	\$	350	\$ 210.00
Thomas Giordano	01/30/20	Began to draft detailed email to project team regarding the identified ownership depiction issue related to four entities in the MundipharmaMEA GmbH organization structure that had effects across multiple entities' organization structures	0.7	\$	350	\$ 245.00
Michael Land	01/30/20	Review of United Kingdom disposition scenarios for purposes of assessing the optimal structure to maximize distributable proceeds	1.1	\$	534	\$ 587.40
Dawn Krishnamurthy	01/30/20	Review structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Argentina - Bermuda	1.2	\$	695	\$ 834.00
Michael Land	01/30/20	Review of Singapore cash flow calculation with regards to asset versus stock sale	1.3	\$	534	\$ 694.20

KPMG LLP Monthly Fee Statement Page 68 of 82

191293838041941shl D 000089350-Eiled Filed 0033206/210 nt 0 25 of 12002690274:2181 air Extribit 11 ent Copy of KPMG First Month 13/1 For 0 84 pplication Pg 72 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Jess Commisso	01/30/20	Continue (from earlier in the day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	1.4	\$	350	\$ 490.00
Isaac Hirsch	01/30/20	Continued (from previous day) to perform Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments	1.4	\$	819	\$ 1,146.60
Ashley Armfield	01/30/20	Meeting with A. Armfield and M. Land (KPMG) to discuss updates required to be performed to the cash tax model, including but not limited to the payment of intercompany obligations and preferred equity in connection with the proposed disposition of the Mundipharma entities.	1.4	\$	534	\$ 747.60
Michael Land	01/30/20	Meeting with A. Armfield and M. Land (KPMG) to discuss updates required to be performed to the cash tax model, including but not limited to the payment of intercompany obligations and preferred equity in connection with the proposed disposition of the Mundipharma entities.	1.4	\$	534	\$ 747.60
Frank Caratzola	01/30/20	1.0 Performed research regarding branch ordering rules with regard to how FTCs would be treated in the client structure 1.0 Performed research regarding Section 731 distributions with regard to how FTCs would be treated in the client structure	2.0	\$	534	\$ 1,068.00
Devon Rowles	01/30/20	Continue (same day) to revise structure deck for Purdue Pharma (Canada) (per A. Armfield and M. Land – both of KPMG) with specific regards to individual country dispositions and foreign tax consequences	2.4	\$	350	\$ 840.00
Dawn Krishnamurthy	01/30/20	Review structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Brazil- Finland	2.4	\$	695	\$ 1,668.00
Ashley Armfield	01/30/20	0.8 Performed research related to Internal Revenue Code Section 904(b) relating to foreign tax credit limitation calculation pursuant to cash tax model; 0.8 Performed research related to Internal Revenue Code Section 901 relating to foreign tax credits pursuant to cash tax model. 0.9 Performed research related to Internal Revenue Code Sections 861-865 relating to income sourcing pursuant to cash tax model.	2.5	\$	534	\$ 1,335.00
Michael Land	01/30/20	1.1 Review of Germany disposition scenarios with regards to asset versus stock sale 1.4 Review of Singapore disposition scenarios with regards to asset versus stock sale	2.5	\$	534	\$ 1,335.00

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth 13/2 Feetes Application Pg 73 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Ashley Armfield	01/30/20	Performed structural updates to the cash tax model (based on comments received from I. Hirsch and discussions with M. Land-both KPMG) including the calculation of foreign tax credits and income classification.	2.8	\$	534	\$ 1,495.20
Michael Land	01/30/20	1.4 Review of Canada disposition scenarios with regards to asset versus stock sale 1.6 Review of Canada cash flow calculation regarding asset versus stock sale	3.0	\$	534	\$ 1,602.00
Dawn Krishnamurthy	01/30/20	2.1 Review of structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: France - Japan; 0.9 Review of structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Luxembourg - UK.	3.0	\$	695	\$ 2,085.00
Thomas Giordano	01/30/20	Further refined the structure deck disposition scenarios for Mundibiopharma Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to consistent).	3.4	\$	350	\$ 1,190.00
Pete DiMatteo	01/30/20	Continue, from previous day, to draft PowerPoint presentation depicting contemplated transactions	3.5	\$	650	\$ 2,275.00
Thomas Giordano	01/30/20	Further refined the structure deck disposition scenarios for Mundipharma Medical Company Limited, as of 1/30/2020, with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to be consistent).	3.5	\$	350	\$ 1,225.00
Pete DiMatteo	01/30/20	Continue (from 1/29) to update outline detailing section 162 research to include results of additional research for purposes of determining whether a deduction is permissible for settlement payments.	3.7	\$	650	\$ 2,405.00
Frank Caratzola	01/30/20	Continued (from 1/29/2020) to perform research regarding foreign tax credit ("FTC") rules under sections 901/904 as they related to the specific entity structures in client's facts	3.7	\$	534	\$ 1,975.80
Jess Commisso	01/30/20	Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	3.9	\$	350	\$ 1,365.00

KPMG LLP Monthly Fee Statement

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	F	Rate	Amount
Devon Rowles	01/30/20	Continued (from 1/28) to revise the structure deck for Purdue Pharma (Canada) (per A. Armfield and M. Land – both of KPMG) with specific regards to individual country dispositions and foreign tax consequences.	3.9	\$	350	\$ 1,365.00
Jess Commisso	01/30/20	Continued (from 1/29) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	3.9	\$	350	\$ 1,365.00
Nick Morgan	01/30/20	Review of Purdue Term Sheet (0.5) and Purdue Term Sheet Summary client deliverable (0.5) with specific regards to facts of the case in order to render future advice per client deliverables.	1.0	\$	350	\$ 350.00
Nick Morgan	01/30/20	Review of client deliverable structure deck provided by KPMG International tax (P. DiMatteo and T. Giordano) with specific regards to deal transaction scope of work From KPMG International service line.	1.3	\$	350	\$ 455.00
Nick Morgan	01/30/20	Review of documentation (provided by client documents as well as documents included in VDR) with focus on deal transaction / scope of work.	2.7	\$	350	\$ 945.00
Ashley Armfield	01/31/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to cash tax model related to preferred equity distributions	0.4	\$	534	\$ 213.60
Michael Land	01/31/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to cash tax model related to preferred equity distributions	0.4	\$	534	\$ 213.60
Ashley Armfield	01/31/20	Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	0.7	\$	534	\$ 373.80
Nick Morgan	01/31/20	Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	0.7	\$	350	\$ 245.00
Devon Rowles	01/31/20	Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	0.7	\$	350	\$ 245.00
Michael Land	01/31/20	Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences	0.7	\$	534	\$ 373.80

KPMG LLP Monthly Fee Statement Page 71 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthTy4Fefe8Application Pg 75 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 534	\$ 373.80
Nick Morgan	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 350	\$ 245.00
Devon Rowles	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 350	\$ 245.00
Michael Land	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 534	\$ 373.80
Jess Commisso	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 350	\$ 245.00
Michael Land	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 534	\$ 373.80
Pete DiMatteo	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 650	\$ 455.00
Thomas Giordano	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 350	\$ 245.00
Jess Commisso	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	0.7	\$ 350	\$ 245.00
Michael Land	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	0.7	\$ 534	\$ 373.80

KPMG LLP Monthly Fee Statement Page 72 of 82

1912323649494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth No Feet & Application Pg 76 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Ra	ite	Amount
Pete DiMatteo	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	0.7	\$	650	\$ 455.00
Thomas Giordano	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	0.7	\$	350	\$ 245.00
Michael Land	01/31/20	Performed research related to foreign tax credit calculations with regards to the Purdue Pharma cash tax model	1.1	\$	534	\$ 587.40
Isaac Hirsch	01/31/20	Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments.	1.2	\$	819	\$ 982.80
Ashley Armfield	01/31/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax credits	1.2	\$	534	\$ 640.80
Michael Land	01/31/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax credits	1.2	\$	534	\$ 640.80
Jess Commisso	01/31/20	Extract and concurrently compile newly uploaded United Kingdom tax documentation from the virtual data room to share with the global team pursuant to their tax analysis.	1.3	\$	350	\$ 455.00
Jess Commisso	01/31/20	Continue, from earlier in the day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	1.4	\$	350	\$ 490.00
Michael Land	01/31/20	0.8 Reviewed Ernst & Young question & answer documentation uploaded to the virtual data room with focus on the independent associated companies tax profile; 0.8 review of Ernst & Young updated financial information on jurisdiction-by-jurisdiction basis uploaded to the virtual data room to determine potential high priority jurisdictions	1.6	\$	534	\$ 854.40
Frank Caratzola	01/31/20	Analyzed entity list created by EY in comparison with KPMG entity list as requested by P. DiMatteo (KPMG) to determine the accuracy of KPMG entity list / identify any potential discrepancies.	1.6	\$	534	\$ 854.40
Pete DiMatteo	01/31/20	Continued, from previous day) to perform analysis regarding section 162 deductions in the context of trust/partnership trade or business attribution as part of overall analysis regarding allowability of deductions.	2.2	\$	650	\$ 1,430.00

KPMG LLP Monthly Fee Statement Page 73 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthTy6Fefe8Application Pg 77 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Devon Rowles	01/31/20	Extract and concurrently compiled Singapore tax documentation from the virtual data room as of 1/31/2020 to share with Singapore pursuant to their tax analysis.	2.3	\$	350	\$ 805.00
Dawn Krishnamurthy	01/31/20	2.4 Manager review of Mundipharma ownership structures for purpose of depicting disposition scenarios; 0.3 Review of EY Q&A document (a follow up to the EY financial vendor Due Diligence report which we reviewed for relevant tax information) with entity listing with focus on the IAC listing tab (which I compared to our information on entities in the Mundipharma group) to ensure a complete listing of IAC entities so that we can accurately gain insight regarding which entities may potentially to be sold / where the assets are located.	2.7	\$	695	\$ 1,876.50
Arpit Kakar	01/31/20	Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Private Limited to determine Tax reserves, Open tax audits or controversies as well as tax attribute carryforwards and concurrently drafted information summary of such details as appearing in the audited financials.	2.8	\$	640	\$ 1,792.00
Naman Gupta	01/31/20	Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Healthcare Private Limited and Win-Medicare Private Limited to determine Tax reserves, Open tax audits or controversies and Tax attribute carryforwards while concurrently preparing an information summary of same as appearing in the audited financials.	3.1	\$	640	\$ 1,984.00
Dawn Krishnamurthy	01/31/20	Performed Manager review of Mundipharma draft disposition scenarios deck (Canada).	3.1	\$	695	\$ 2,154.50
Pete DiMatteo	01/31/20	Draft structuring deck depicting transactions related to Mundipharma Deutschland GmbH & Co. KG (Germany) stock/asset sales and tax consequences	3.3	\$	650	\$ 2,145.00
Frank Caratzola	01/31/20	Performed research regarding foreign tax credits - as they relate to Purdue Pharma (client) structure	3.4	\$	534	\$ 1,815.60
Nidhi Jain	01/31/20	Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Beauty Products Private Limited to determine Tax reserves, Open tax audits or controversies and Tax attribute carryforwards; and prepared information summary of such details as appearing in the audited financials.	3.5	\$	640	\$ 2,240.00
Ashley Armfield	01/31/20	2.9 Performed research related to differential tax rate relating to foreign tax credit calculation pursuant to Purdue Pharma cash tax model; 0.9 Updating cash tax model to incorporate rate differential concept per results of research.	3.8	\$	534	\$ 2,029.20

KPMG LLP Monthly Fee Statement

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPth/17/Tee8Application Pg 78 of 85

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate		Amount
Thomas Giordano	01/31/20	Additional updates to the Purdue Pharma structure deck disposition scenarios related to Mundipharma Medical Company Limited and Mundibiopharma Limited	3.8	\$	350	\$ 1,330.00
Jess Commisso	01/31/20	Continued, from 1/30, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	3.9	\$	350	\$ 1,365.00
Howard Steinberg	01/31/20	Performed Partner review of tax summary for purposes of determining high priority jurisdictions	1.7	\$	856	\$ 1,455.20
Nick Morgan	01/31/20	Reviewed bankruptcy trust documentation with focus on types of distributing entities for tax posture purposes.	1.0	\$	350	\$ 350.00
Nick Morgan	01/31/20	Created UK structure deck for the client deliverable for entity #2	1.4	\$	350	\$ 490.00
Nick Morgan	01/31/20	Created UK structure deck for the client deliverable for entity #1	1.6	\$	350	\$ 560.00
Nick Morgan	01/31/20	Continued (same day) creation of structure deck formation for UK entities with focus on providing provided additional structuring steps for each entity.	2.5	\$	350	\$ 875.00
		Subtotal Tax Consulting Services	1,311.1			\$ 702,712.00
		Less KPMG Voluntary Reduction				\$ (130,000.00)
		Total Tax Consulting Services				\$ 572,712.00

KPMG LLP Monthly Fee Statement Page 75 of 82

19129323649494shl Dobooc9950-EileoFiDedO333206/210nteEntel0edO33320612502690274:2131ainEtatribitment Copy of KPMG First MoPith 17/8 Fores Application Pg 79 of 85

EXHIBIT C2

Purdue Pharma L.P. Case No. 19-23649

Non -Working Travel Time December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	ate	Amount
Isaac Hirsch	01/16/20	Non-working travel time (roundtrip) from home in Livingston, NJ and KPMG NYC office (560 Lexington Ave) to attend meeting related to Purdue Pharma bankruptcy matter.	3.0	\$	819	\$ 2,457.00
Isaac Hirsch	01/27/20	Non-working travel time (roundtrip) from home in Livingston, NJ and KPMG NYC office (560 Lexington Ave) to attend meeting related to Purdue Pharma bankruptcy matter.	3.0	\$	819	\$ 2,457.00
		Subtotal Non-Working Travel Time	6.0			\$ 4,914.00
		Less 50% Rate Reduction				\$ (2,457.00)
		Less KPMG Voluntary Reduction				\$ (2,457.00) (1)
		Total Non-Working Travel Time				\$ -

⁽¹⁾ KPMG is taking a voluntary reduction of non-working travel time.

19129323649494shl Dobooc9950-EileoFiDedO333206/210nteEntel0edO33320612502690274:2131ainExtribitment Copy of KPMG First MoPith 17/9Foe684.pplication Pg 80 of 85

EXHIBIT C3

Purdue Pharma L.P. Case No. 19-23649

Retention Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	ŀ	Rate	A	Amount
Monica Plangman	01/03/20	Call with S. Carlin (KPMG Office of General Counsel) regarding retention 0.2; Revise Declaration and Order and transmit to counsel 1.1	1.3	\$	264	\$	343.20
Monica Plangman Monica Plangman	01/09/20 01/09/20	Create schedule 1 and 2 referenced in KPMG Declaration (1.1); review email from counsel regarding retention (0.1); review revised retention documents and concurrently email E. Dalmanieras (Foley Hoag) and S Carlin (KPMG) to advise on same, providing a summary of revisions and pertinent details (0.5); review responses received regarding same from S. Carlin and E. Dalmanieras (0.2) Request confirmation from S. Carlin (KPMG) regarding revised language in the Order (0.1) Transmit email to H Steinberg regarding retention (0.1);	2.0	\$	264	\$	528.00 79.20
Ç		transmit Schedules 1 and 2 of Declaration to Debtors' counsel along with an update regarding review of retention documents (0.2).					
		Total Retention Services	3.6			\$	950.40

19123230494shl Doboo 89350-Eiled Filed 033206/210 nt Enter 02003320612502690274:2131 ain Extribit munt Copy of KPMG First Month By OF See Application Pg 81 of 85

EXHIBIT C4

Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	I	Rate	Amount
Wendy Shaffer	01/06/20	0.4 initial communication with A. Armfield (KPMG) regarding Purdue Pharma bankruptcy including information related to use of KPMG member firms and next steps; 0.1 follow-up communication with M. Plangman (KPMG) regarding same; 2.5 begin to draft multiple emails to KPMG foreign member firms including creation of Templates (by country) for inclusion in email to provide US bankruptcy time / expense detail requirements to facilitate fillings in the bankruptcy court.	2.9	\$	202	\$ 585.80
Wendy Shaffer	01/07/20	0.1 Call with P. Reer (KPMG) regarding German KPMG professionals currently working in the US performing services for Purdue Pharma in order to provide correct time/expense timekeeping guidelines and 0.1 forward US SYNC instructions as requested to appropriate team members	0.2	\$	202	\$ 40.40
Wendy Shaffer	01/08/20	Drafted additional emails to new Purdue team members (US and Foreign member firms) including updates to templates to facilitate billings in the bankruptcy court.	0.5	\$	202	\$ 101.00
Wendy Shaffer	01/10/20	Draft email to new team members for Purdue as of 1/10/2020 to facilitate billing in the bankruptcy court.	0.2	\$	202	\$ 40.40
Dawn Krishnamurthy	01/13/20	0.1 Discussion with W. Shaffer (KPMG) regarding services to be billed in KPMG 1st monthly fee application performed by KPMG foreign member firms.	0.1	\$	695	\$ 69.50
Wendy Shaffer	01/13/20	Discussion with D. Krishnamurthy (KPMG) regarding services to be billed in KPMG 1st monthly fee application performed by KPMG foreign member firms.	0.1	\$	202	\$ 20.20
Wendy Shaffer	01/13/20	0.2 Updated exhibit C1 of Purdue 1st monthly fee application to include data from KPMG member firms - China and Germany; 0.1 review court docket to extract copy of Purdue ICO, 0.2 Updated exhibit A of Purdue 1st monthly fee application to include additional KPMG team members.	0.5	\$	202	\$ 101.00
Wendy Shaffer	01/14/20	0.4 begin initial review of documentation email communication to date related to Purdue Pharma bankruptcy; 0.9 begin to create Purdue Pharma 1st monthly fee application exhibits; 0.5 Updated exhibit C1 of Purdue 1st monthly to include data received from KPMG foreign member firms as of 1/14/20.	1.8	\$	202	\$ 363.60
Wendy Shaffer	01/15/20	Continued, same day, to update exhibit C1 of Purdue Pharma to include data received from professionals as of 1/15/2021.	1.9	\$	202	\$ 383.80
Wendy Shaffer	01/15/20	Updated exhibit C1 of Purdue Pharma to include data received from professionals as of 1/15/2020	3.8	\$	202	\$ 767.60

KPMG LLP Monthly Fee Statement Page 78 of 82

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPthBy1Fefe8Application Pg 82 of 85

EXHIBIT C4

Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	R	ate	Amount
Wendy Shaffer	01/17/20	0.1 Review of Purdue Pharma engagement letter with regards to rates to included in 1st monthly fee application- send communication to M. Plangman (KPMG) related to same; 1.6 Updates to exhibit C1 of Purdue Pharma to include data received from professionals as of 1/17/2020; 1.0 Call with M. Plangman (KPMG) regarding initial questions related to Purdue engagement including questions regarding rates, services to be performed by KPMG foreign member firms and related templates to be utilized to capture time and expense detail to be submitted in the bankruptcy court.	2.7	\$	202	\$ 545.40
Wendy Shaffer	01/22/20	3.2 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from professionals as of 1/22/20; 0.1 drafted email to G. Flasser and D. Brogan (both Bayard law) re KPMG introduction and questions regarding assistance with filing / service of monthly and interim applications.	3.3	\$	202	\$ 666.60
Wendy Shaffer	01/27/20	0.3 Review of Purdue Pharma Interim Compensation Order to facilitate billings in the bankruptcy court; 0.3 Draft email to KPMG Partners/team leads to provide copy of ICO and summary of timeline process related to same; 1.8 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/27/2020	2.4	\$	202	\$ 484.80
Wendy Shaffer	01/27/20	0.2 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG member firm in South Korea as of 1/27/2020; 0.1 email to B. Defliese (KPMG) regarding time detail received for foreign member firms and next steps; 0.2 Reviewed KPMG work in progress reports to confirm billable hours for KPMG through 1/26/2020; 0.1 email to C. Nunez (KPMG) regarding rates to be used in Exhibit A of Purdue Pharma monthly fee applications.	0.6	\$	202	\$ 121.20
Wendy Shaffer	01/28/20	3.5 Updated to exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from professionals as of 1/22/20; 0.1 call with C. Nunez (KPMG) regarding rates to be included in Purdue Pharma 1st monthly fee application.	3.6	\$	202	\$ 727.20
Wendy Shaffer	01/28/20	0.1 Follow-up communication via email with C. Nunez (KPMG) regarding rates to be included in Purdue Pharma 1st monthly fee application; 0.2 noted results of discussions with C. Nunez (KPMG) for future reference and go forward; 1.2 Begin to populate rates in Exhibit A of Purdue Pharma 1st monthly fee application per direction from C. Nunez (KPMG)	1.5	\$	202	\$ 303.00

KPMG LLP Monthly Fee Statement

19123236494shl Dobo&9350-EiledFiDedO33206/210nteEntel0edO3320612602690274:2131ainEtatibitment Copy of KPMG First MoPtth By2Feetes Application Pg 83 of 85

EXHIBIT C4

Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate		Amount
Wendy Shaffer	01/29/20	Continue, same day, to update exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/29/2020.	0.3	\$ 202	2 \$	60.60
Wendy Shaffer	01/29/20	0.1 created exhibit for Non-working travel time (C3) in Purdue Pharma 1st monthly fee application; 0.3 communication and forwarding of emails to B. Defliese (KPMG) of foreign member firm emails and items requiring follow-up regarding summary of fees; 1.9 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG foreign member firms as of 1/29/2020.	2.3	\$ 202	2 \$	464.60
Wendy Shaffer	01/29/20	Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/29/2020.	3.9	\$ 202	2 \$	787.80
Wendy Shaffer	01/30/20	Updated exhibit A of Purdue Pharma 1st fee application to include rates / titles for South Korea	0.1	\$ 202	2 \$	20.20
Wendy Shaffer	01/31/20	Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/31/2020	1.1	\$ 202	2 \$	222.20
		Total Fee Application Preparation Services	33.8		\$	6,876.90

1912323049494shl D@0089350-EiledFi02d033206/210nteEntel02d0332061250269024:2181ainEtatibitment Copy of KPMG First MoPtth By3Fee68Application Pg 84 of 85

EXHIBIT D

Purdue Pharma L.P. Case No. 19-23649

Summary of Out of Pocket Expenses December 23, 2019 through January 31, 2020

Category	Amount				
Airfare	\$	170.28			
Lodging	\$	335.95			
Meals	\$	148.68			
Ground Transportation	\$	334.13			
Miscellaneous	\$				
Expense Subtotal	\$	989.04			
Less KPMG Voluntary Reduction as noted on Exhibit D1	\$	(374.11)			
Total	\$	614.93			

191293230494shl Doboo&9950-EiledFiDedO333206/210ntdEntel0edO33320612802690274:2131ainEtatibitment Copy of KPMG First MoPithBy4Fefe8Application Pg 85 of 85

EXHIBIT D1

Purdue Pharma L.P. Case No. 19-23649

Detail of Out of Pocket Expenses December 23, 2019 through January 31, 2020

Name	Date	Description	A	Amount	-
Mark Hoffenberg	01/16/20	One way coach class airfare for travel from Washington, DC to New York to attend Purdue client meeting.	\$	170.28	
		Air Fare Subtotal	\$	170.28	
Mark Hoffenberg	01/17/20	Hotel fee incurred on night of 1/16 with check out on 1/17 while traveling to attend Purdue Pharma meeting.	\$	335.95	
		Lodging Subtotal	\$	335.95	-
Michael Land	01/10/20	Business Meals: KPMG Participants: A. Armfield, D. Rowles, M. Land	\$	9.15	(1)
Ashley Armfield	01/13/20	Overtime meals while performing services for Purdue. KPMG Participants: A. Armfield, D. Rowles, J. Commisso, M. Land	\$	49.97	(1)
Ashley Armfield	01/14/20	Business meals working late team coffee A. Armfield, M. Land, J. Commisso, D. Rowles	\$	32.56	(1)
Jess Commisso	01/15/20	Overtime meals incurred while performing services for Purdue Pharma. KPMG Participants: A. Armfield, D. Rowles, J. Commisso, M. Land	\$	57.00	
		Meals Subtotal	\$	148.68	
Devon Rowles	01/05/20	Uber fees incurred for travel from office to home while working late on Purdue engagement.	\$	24.13	(1)
Isaac Hirsch	01/10/20	Parking fee incurred while attending meeting to discuss client business	\$	30.00	(1)
Michael Land	01/10/20	Uber fee for travel while performing services for Purdue	\$	34.79	(1)
Ashley Armfield	01/14/20	Uber fee for late night travel from office to home working on client engagement.	\$	21.65	(1)
Devon Rowles	01/14/20	Uber fees incurred for travel from office to home while working late on Purdue engagement.	\$	26.01	(1)
Ashley Armfield	01/15/20	Uber fee for late night travel from office to home working on client engagement.	\$	20.96	(1)
Michael Land	01/15/20	Uber fee for travel while performing services for Purdue	\$	33.62	(1)
Ashley Armfield	01/16/20	Uber fee for late night travel from office to home working on client engagement.	\$	18.26	(1)
Isaac Hirsch	01/16/20	Mileage for meeting to discuss client business (14 miles at \$0.575/mile)	\$	8.05	(1)
Mark Hoffenberg	01/16/20	Uber fee for travel from NYC LaGuardia to hotel in New York City while traveling to attend Purdue client meetings.	\$	51.70	
Mark Hoffenberg	01/17/20	Cab fare incurred in New Yok City to attend client meeting	\$	39.96	(1)
Mark Hoffenberg	01/17/20	Parking fees for personal car at airport while traveling to perform services for Purdue.	\$	25.00	(1)
		Total Ground Transportation	\$	334.13	
		Miscellaneous Subtotal	\$	-	
		Subtotal Out of Pocket Expenses	\$	989.04	•
		Less KPMG Voluntary Reduction	\$	(374.11)	(1)
		Total Out of Pocket Expenses	\$	614.93	

 $^{^{(1)}}$ KPMG is taking a voluntary reduction of expenses under \$50.00.

KPMG LLP Monthly Fee Statement Page 82 of 82